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Abstract 
Inhibition studies of serine hydrolases by cyclic phosphates and phosphonates 
 
(June 2010) 
 
Supratik Dutta, M.S., University of Missouri, St. Louis, MO, USA. 
 
Chair of Committee: Dr. C. M. Dupureur 
 
The serine hydrolase superfamily is one of the largest known enzyme families 
comprising approximately 1% of the predicted protein product in human genome.  This 
family of enzymes contains a catalytic triad that is mainly consists of serine, aspartic 
acid/glutamic acid and histidine residues in their active sites.  It has been proposed that 
the potential drug targets for Alzheimer‟s disease and diabetes type 2 are enzymes that 
belong to this enzyme family.   
Acetylcholinesterase (AChE) is an enzyme that catalyzes the breakdown of 
acetylcholine, a neurotransmitter that helps transport information from one nerve cell to 
another.  Breakdown of acetylcholine in Alzheimer‟s disease patients enhances memory 
loss, which could be reduced if AChE is inhibited.  Cyclophostin, a bicyclic phosphate, is 
a natural product inhibitor of AChE having an IC50 of 8 e-4 µM.  The laboratory-
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synthesized mono- and bicyclic analogs of phosphonate analog of cyclophostin exhibited 
low µM potency against human AChE.  It is established that these analogs covalently 
modify the active site of AChE and do not dissociate from the active site upon treatment 
with oximes.  From a comparative analysis of kinetic data these compounds are less toxic 
and milder than the existing AChE inhibitors and can be used as potential 
chemotherapeutic agent against Alzheimer‟s disease. 
Hormone-sensitive lipase (HSL) is another serine hydrolase enzyme that 
hydrolyzes lipids in the form of triglycerides.  It is a homodimer of 84 kDa subunits and 
is mostly found in adipose tissues.  HSL is a potential drug target for diabetes type 2.  
The activity of HSL must be inhibited in insulin deficient patients to lower the risk of 
associated cardiovascular disease.  Cyclipostin is a natural product inhibitor of HSL.  
Laboratory-synthesized monocyclic phosphonate analogs of cyclipostin having varying 
C-chain length exhibited µM potency against rat HSL.  The potency of these analogs 
improved upon introducing longer C-chain like C16.  This class of compounds showed an 
aggregation property that affected their potency against the enzyme.  The attachment of 
the C-chain at the P-center of the monocyclic phosphonate analog considerably improved 
the potency (almost 10 fold).   
HSL has not been crystallized yet, so the biophysical events triggering the 
translocation of the enzyme towards lipid storage modules upon phosphorylation are not 
well established.  It is shown that the translocation of the enzyme happens due to the 
hydrophobic surface exposure of the protein upon phosphorylation.  It is revealed from 
fluorescence data that at least S563 and S565 phosphorylation sites do not have a 
iv 
 
significant effect on the exposure process.  In vivo translocation experiments revealed 
that for translocation, the β-adrenergic hormone (forskolin) treatment is important for the 
co-localization of protein to the lipid. 
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CHAPTER I 
INTRODUCTION  
1.1 Introduction to Serine hydrolase (SH): 
Serine hydrolases (SHs) are a remarkably large and diverse family of enzymes 
that comprise approximately 1% of the protein products of the mammalian genome 
(Rawlings et al.; Nelson et al. 1999).  These include almost 100 serine proteases (e.g., 
trypsin, thrombin, elastase) and more than 150 SHs that hydrolyze metabolites and 
peptides.  The SH family consists of esterases (e.g., acetylcholinesterase (AChE)), lipases 
(e.g., hormone-sensitive lipase (HSL), cytosolic phospholipase A2 (cPLAs), peptidases 
(e.g., dipeptidylpeptidase-IV (DPPIV)), and amidases (e.g., fatty acid amide hydrolase 
(FAAH)).  SHs play an important role in many physiological and pathological processes, 
which include inflammation (Clark et al. 1995), cancer (DeClerck et al. 1997), neural 
plasticity (Yoshida and Shiosaka 1999), angiogenesis (Mignatti and Rifkin 1996), and 
diabetes (Gorrell 2005).  Most of the SHs (>60%) contain the α/β-hydrolase fold 
secondary structure (Fig. 1.1) (Contreras et al. 1996); however, there are other subclasses 
of SHs which adopt different types of folds and catalytic machinery, including amidases 
(serine-lysine-lysine triad) (Bracey et al. 2002; Gorrell 2005) and patatin domain 
containing lipases (serine-aspartic acid dyad).  Generally, SHs contain the serine-
histidine-aspartic acid catalytic triad (Bracey et al. 2002; Rawlings et al. 2010); it utilize 
a conserved serine nucleophile to hydrolyze ester, thioester, and amide bonds in both 
proteins and small molecule substrates (e.g., metabolites).  This reaction is done by 
attacking substrate esters or amides at the sp2 carbon by a base-activated 
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Figure 1.1:  Secondary structure of SHs (A-26).  The secondary structures of the SHs 
containing the α/β-hydrolase fold that consists of 8 α-helices (rectangular boxes) and 7 β-
sheets (black arrows) in an alternate manner.  This unique α/β-hydrolase fold structure 
brings the serine, glutamic acid, and histidine in proximity to create the catalytic triad for 
catalysis.  Catalytic serine is located between β5 and α5, 6, whereas other catalytic triad 
residues glutamic acid and histidine are located at β7/α
4 7,8 and β8/α
2
8 junctions, 
respectively.  Adapted from (Contreras et al. 1996). 
Glu 
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serine nucleophile (Fig. 1.2).  An active site water molecule then cleaves the resulting 
acyl-enzyme intermediate to conclude the substrate hydrolysis and revive the hydrolase 
active form.   
1.2  Introduction to Acetylcholinesterase (AChE): 
1.2.1  Physiological function: 
Acetylcholinesterase (acetylcholine acetylhydrolase, EC 3.1.1.7; abbreviated as 
AChE) and its natural substrate acetylcholine (ACh) function in the central and 
peripheral nervous system to transmit action potentials across neurons and 
neuromuscular synapses (Rosenberry 1975; Rosenberry 1975).  AChE catalyses the 
hydrolysis of the cationic neurotransmitter ACh to choline and acetic acid (Fig. 1.3).  In 
response to the action potential in a pre-synaptic neuron, ACh is released at the synapse 
(Fig. 1.4).  Then, ACh binds to the acetylcholine receptor at the post synaptic neuron and 
opens the Na+ ion channel.  After a series of reaction processes, the action potential 
triggers the post-synaptic neuron.  Finally, ACh is hydrolyzed by extrinsic membrane 
bound AChE to acetic acid and choline (Fig. 1.3) and terminates the ACh receptor 
mediated ion-gating (Rosenberry 1975; Maelicke and Albuquerque 2000) (Fig. 1.4).  In 
neuronal diseases like Alzheimer‟s disease (AD), the neuron cells suffer from severe 
damage and produce less ACh and in turn the whole ion-gating process hinders leading 
to acute memory loss.  Researchers have targeted AChE to minimize the ACh hydrolysis 
and control the memory loss process in the AD disease condition. 
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Figure 1.2:  Acylation and deacylation steps of SHs at the active site.  The SHs active 
site contains a catalytic triad, which consists of serine, histidine, and glutamic acid.  By 
electron relay process, it hydrolyses the substrate esters (X = O atom) or amides (X = N-
atom).  As shown in the acylation reaction, the serine does the nucleophilic attack at the 
carbonyl C-center and forms an acyl-serine intermediate.  The active site water molecule 
does the nucleophilic attack at the carbonyl C-center of acyl-moiety of acyl-serine and 
forms the ultimate reaction product as acid and alcohol (when substrate is ester) or amine 
(when substrate is amide). 
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Fig. 1.3:  Hydrolysis of natural substrate acetylcholine (ACh) by AChE.  
Acetylcholine (ACh) is hydrolyzed by AChE to form acetic acid and choline.  The 
mechanism of hydrolysis is given in Fig. 1.2.  The positively charged choline moiety of 
ACh binds the catalytic anionic site residues and directs the business end (the acyl part) 
of the substrate to the catalytic triad to pursue the chemical hydrolysis step.   
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Fig. 1.4:  Mechanism of neuron to neuron information transfer and role of AChE.  
a)  Signal comes as action potential (green line) in pre-synaptic neuron.  The action 
potential attracts the Ca+2 ions (white spheres) to bind the ACh-containing (shown as 
combination of red sphere and yellow triangle) vesicles.  b)  Ca+2 ions rupture the vesicle 
to release the ACh to the synapse (junction between pre- and post-synaptic nueron).  c) 
The ACh binds to the ACh-receptor on the post-synaptic neuron and opens the Na+ ion 
(shown as blue spheres) channel (shown as red rods).  d) Na+ ions pass through the 
channel and thus carry electrical information generated in pre-synaptic neuron.  Adapted 
from (Maelicke and Albuquerque 2000). 
Presynaptic 
neuron 
Postsynaptic 
neuron a) b) 
d) c) 
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In addition to the involvement in terminating ACh-mediated neurotransmission, 
AChE engages itself in various physiological processes through its role in cell 
differentiation, regulation of cell proliferation, and cell survival.  The effect of AChE in 
these process depends upon the type of cell involved, the differentiation state, and the 
binding with protein partners (Soreq et al. 1994).  It is reported that suppression of AChE 
gene in hematopoietic stem cell increases the tendency of cell proliferation, which 
directly indicates the involvement of AChE in apoptotic processes (Robitzki et al. 1998; 
Ben-Ari et al. 2006).  The exact mechanism of AChE‟s function in apoptosis is still 
under investigation.  Scientists have found some evidence of involvement of AChE in 
type 2 diabetes mellitus through insulin resistance state and lipid metabolism process 
(Sridhar et al. 2006). 
1.2.2  AChE structure: 
Recombinant human AChE is a homotetramer of 64 kDa subunits.  The 
molecular weight of the protein varies from species to species e.g., electric eel AChE has 
a molecular weight of 70 kDa and house fly AChE has a molecular weight of 76 kDa.  
Each monomer of human AChE contains 579 amino acids.  Fig. 1.5 shows the 
monomeric subunit of recombinant human erythrocyte AChE (1B41.pdb).  The structure 
contains an α/β-hydrolase fold, a common secondary structural element in SH (Ollis et 
al. 1992).  The active site Ser203 is located at the junction between β5 and α5,6, whereas 
other catalytic triad members, Glu334 and His447 are located at β7 and α1,8, respectively 
(Fig. 1.1 and Fig. 1.5).  The AChE tertiary structure is stabilized by three  
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Fig. 1.5:  Crystal structure of a subunit of the recombinant human AChE 
(B41.pdb).  The tertiary structure of a subunit of recombinant human AChE is shown in 
the Figure.  The alternate α-helices (in blue) and β-sheets (in yellow) array can be seen in 
the structure as a part of α/β- hydrolase fold secondary structure.  The catalytic site 
residues Ser203, Glu334, His447, Trp286, and Trp86 are shown in red.  The raw 
structure B41.pdb has been downloaded from Protein data bank and modified using the 
SwissPDB Viewer structural tool. 
Trp 286 
His 447 
Glu 334 
Ser 203 
Trp 86 
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pairs of disulfide loops: Cys69-Cys96, Cys257-Cys269, and Cys409-Cys529.  It is 
believed that the motion of Cys69-Cys96 loop plays a key role in the allosteric 
conformational change of Trp286 upon peripheral ligand binding to the peripheral 
anionic binding site (P-site) (Barak et al. 1995).   
The amino acid sequence of AChE from mammals differs from other eukaryotes 
and insects.  The human AChE amino acid sequence is 65% similar (Fig. 1.6) to that of 
the electric eel AChE, whereas it is only 33% homologous to the house fly AChE amino 
acid sequence (Fig. 1.6).  The low homology between human and house fly AChE has 
provided an opportunity for designing highly efficient and specific insecticides (Weill et 
al. 2002; Pang 2006).   
The active site of the AChE is buried in a gorge (Fig. 1.7).  The catalytic triad is 
located at the bottom of the gorge.  The active site catalytic triad members are Ser203, 
Glu334, and His447.  As discussed above, the catalytic triad hydrolyses ACh by an 
electron relay mechanism. 
In addition to the catalytic triad residues, there are other important residues that 
are involved in substrate binding and transition state stability.  Trp286 at peripheral 
anionic site (PAS or P-site) is one of them (Fig. 1.7).  Trp286 transiently binds the ACh 
substrate and makes an initial selection of the substrate.  There are other P-site members 
like Asp74, Tyr77 and Tyr133 that also contribute to substrate binding at the active site 
gorge.  Trp86 and Phe 338 (Fig. 1.7), which set up the catalytic anionic site (CAS), 
undergo a π-cation interaction with the positively charged choline moiety 
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Human  ----------------------------------------MRPPQCLLHTPSLA 14 
Eel    ----------------------------------------------MKILDALLFP---- 10 
Fly    MARSVRTPISSSSSSSSRSSWSPPSSSSFYSLLSSFKASLTRPSSSSSVAHHLAARNNDI 60 
                                                         . *        
Human SPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPG-GPVSAFLGIPFAEPPM 73 
Eel    ---VIFIMFFIHLSIAQT---DPELTIMTRLGQVQGTRLPVPDRSHVIAFLGIPFAEPPL 64 
Fly    CRGLFATLVILLRMSALTSAMTDHLTVQTTSGPVRGRSVTVQG-RDVHVFTGIPYAKPPV 119 
         ::  : ::    .       .* : .  * ::*  : . .   * .* ***:*:**: 
Human GPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVW 133 
Eel    GKMRFKPPEPKKPWNDVFDARDYPSACYQYVDTSYPGFSGTEMWNPNRMMSEDCLYLNVW 124 
Fly    DDLRFRKPVPAEPWHGVLDATRLPATCVQERYEYFPGFSGEEMWNPNTNVSEDCLFMNIW 179 
       .  **  * * :** .*.**    :.* *     :***.* ******  :*****::*:* 
Human TPYPRPTSP------------------------------TPVLVWIYGGGFYSGASSLDV 163 
Eel    VPATPRPHN------------------------------LTVMVWIYGGGFYSGSSSLDV 154 
Fly    APAKARLRHGRGTNGGEHSSKTDQDHLIHSATPQNTTNGLPILIWIYGGGFMTGSATLDI 239 
      .*                                      .:::******* :*:::**: 
Human  YDGRFLVQAERTVLVSMNYRVGAFGFLALPGSR-----EAPGNVGLLDQRLALQWVQENV 218 
Eel    YDGRYLAHSEKVVVVSMNYRVSAFGFLALNGSA-----EAPGNVGLLDQRLALQWVQDNI 209 
Fly    YNAEIMSAVGNVIVASFQYRVGAFGFLHLSPVMPGFEEEAPGNVGLWDQALALRWLKENA 299 
      *:.. :    ..::.*::***.***** *         ******** ** ***:*:::*  
Human AAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRR 278 
Eel    HFFGGNPKQVTIFGESAGAASVGMHLLSPDSRPKFTRAILQSGVPNGPWRTVSFDEARRR 269 
Fly    RAFGGNPEWMTLFGESAGSSSVNAQLMSPVTRGLVKRGMMQSATMNAPWSHMTSEKAVEI 359 
         ***:*  :*:******::**. :*:** :*  . *.::**.. *.**  :   :* .  
Human ATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDF 338 
Eel    AIKLGRLVGCP----DGNDTDLIDCLRSKQPQDLIDQEWLVLPFSGLFRFSFVPVIDGVV 325 
Fly    GKALVNDCNCNASLLPENPQAVMACMRQVDAKTISVQQWNSYS--GILSYPSAPTIDGAF 417 
      .  * .  .*       *   :: *:*   .: :  ::*   .  .:: :. .*.:** . 
Human LSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPG-FSKDNESLISRAEFLAGVRVG 397 
Eel    FPDTPEAMLNSGNFKDTQILLGVNQNEGSYFLIYGAPG-FSKDNESLITREDFLQGVKMS 384 
Fly    LPADPMTLLKTADLSGYDILIGNVKDEGTYFLLYDFIDYFDKDDATSLPRDKYLEIMNNI 477 
      :.  * :::::.:: . ::*:*  ::**:***:*.  . *.**: : :.* .:*  :.   
Human VPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGR--------- 448 
Eel    VPHANEIGLEAVILQYTDWMDEDNPIKNREAMDDIVGDHNVVCPLQHFAKMYAQYSILQG 444 
Fly    FQKASQAEREAIIFQYTSWEGNPG-YQNQQQIGRAVGDHFFTCPTNEYAQA--------- 527 
       . :..:   **::::**.*    .  : :: :.  **** ..**  . *            
Human ---LAAQG-----------------ARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGI 488 
Eel    QTGTASQGNLGWGNSGSASNSGNSQVSVYLYMFDHRASNLVWPEWMGVIHGYEIEFVFGL 504 
Fly    ---LAERG-----------------ASVHYYYFTHRTSTSLWGEWMGVLHGDEIEYFFGQ 567 
           * :*                 . *: * * **:*.  *  **** ** ***:.**  
Human PLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRD---PKAPQWPPYTAGAQQYVSLD 545 
Eel    PLEKRLNYTLEEEKLSRRMMKYWANFARTGNPNINVDGSIDSRRRWPVFTSTEQKHVGLN 564 
Fly    PLNNSLQYRPVERELGKRMLNSVIEFAKSGNPAVDGE-------EWPNFSKEDPVYYVFS 620 
      **:   :*   *. :.:*::.   :**::*:*    :       .** ::     :  :. 
Human LRP--LEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKNQFD 603 
Eel    TDS--LKVHKGLKSQFCALWNRFLPRLLNVTENIDDAERQWKAEFHRWSSYMMHWKNQFD 622 
Fly    TDEKIEKLQRGPLAKRCSFWNDYLPKVRSWIGSECENKSSTSASAAIYEMKMQQLTVLAV 680 
             ::::*  :: *::** :**:: .   .  : : . .*.   :.  * : .     
Human HYSKQDRCSDL- 614 
Eel    HYSKQERCTNL- 633 
Fly    AIILTMVNSIFQ 692 
                      : :  
Fig. 1.6:  ClustalW based multiple sequence alignment of human, electric eel, and 
house fly AChE.  The human AChE (Swiss-Prot P22303), electric eel AChE (Swiss-Prot 
ID O42275), and house fly AChE (TrEMBL Q8MXC6) are aligned using ClustalW.  * = 
completely identical amino acids;: = any two are identical. 
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Fig. 1.7:  Active site structure of recombinant human AChE.  The figure shows the 
active site gorge of the human AChE.  At the bottom of the gorge the catalytic triad 
residues Ser203, Glu334, and His447 (in green) are located.  At the upper edge of the 
gorge the P-site residues Trp286, Asp74, and Tyr133 (in blue) are located, whereas, on 
one of the walls of the gorge the catalytic anionic site residues Phe 338 and Trp86 (in 
red) can be seen.  The figure has been generated from 1B41.pdb using SwissPDB Viewer 
structural tool. 
Trp 286 
Asp 74 
Trp 86 
Tyr 133 
His 447 
Glu 334 
Ser 203 
Phe 338 
P-Site 
CAS 
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 of ACh and direct the business end of the substrate to the catalytic triad for catalysis.  
There are several conserved aromatic residues whose aromatic ring constitutes 70% of 
the inner surface of the active site gorge, thereby contributing to form the required 
geometry of the gorge.  Another important component of the AChE active site 
architecture is an involvement of hydrogen bond donors that can stabilize the tetrahedral 
transition state of enzyme-substrate complex by accommodating the negatively charged 
carbonyl oxygen. Structural and modeling studies (Sussman et al. 1991; Shafferman et al. 
1992; Ordentlich et al. 1993) revealed an oxyanion hole formed by peptidic NH groups 
of Gly-121, Gly-122, and Ala-204.  Residues Gly-121, Gly-122, and Gly-120 are part of 
a flexible “glycine loop” which forms one of the active site gorge walls adjacent to the 
catalytic serine.  The glycine loop not only accommodates the oxyanion hole but it is one 
of the most crucial determinants of the active site geometry (Raves et al. 1997).   
1.2.3  General catalytic mechanism: 
AChE catalysis occurs through an acyl-enzyme mechanism that involves 
nucleophilic serine and acid-base histidine residue as shown in Fig. 1.2.  Froede and 
Wilson (1984) showed the existence of formation of acyl-enzyme intermediate by 
trapping the acetyl-enzyme formed during the AChE catalyzed hydrolysis of ACh and 
acetylthiocholine (ATCh) at [S]0 >> Km (Froede and Wilson 1984).  They also showed 
that acylation and deacylation are both involved in the rate limitation of the reaction. 
Terrone Rosenberry (Rosenberry 1975; Rosenberry 1975) proposed a kinetic 
mechanism of AChE catalysis, which involves an induced-fit step (Scheme 1) 
(Rosenberry 1975).  It was suggested that for neutral substrates , an induced-fit  
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Scheme 1:  Kinetic Mechanism for AChE Catalysis that Incorporates an Induced-
Fit Step.  E = AChE, S = substrate, EA = acyl-enzyme, P1, P2 = products, ES1 = 
Michaelis complex. ES2 = induced-fit complex.  k1 and k-1 are the forward and reverse 
rate constant for the formation of Michaelis complex; k2 and k-2 are the forward and 
reverse rate constant for the formation of induced-fit complex; k3 and k4 are the rate for 
the formation of acyl-enzyme and reactivation of the enzyme.  Adapted from 
(Rosenberry 1975; Rosenberry 1975). 
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 conformational change happens after substrate binding but prior to chemical catalysis.  
In Scheme 1, k3 and k4 are the chemical step rate constants for acylation and deacylation, 
respectively.  Rosenberry et al (Rosenberry 1975) solved the steady state kinetic 
parameters (kE and kES) for the mechanism of Scheme 1 as equation 1 and equation 2, 
respectively.   
  Equation 1 
  Equation 2 
where, kES and kE are steady rate constants to emphasize the initial states to which the 
rate constants refer, i.e., bound states and free enzyme state, respectively.  It is seen from 
eqn. 2 that kE represents the conversion of free enzyme and free substrate to a transition 
state(s) in the acylation stage of catalysis, whereas the rate constant kES represents the 
conversion of bound states (ES1 and/or ES2 and/or EA) to transition states for acylation 
and/or deacylation.  Thus, kE always emphasizes the acylation reaction dynamics, 
whereas kES tracks the acylation and/or deacylation. 
It has been shown that AChE has outstanding catalytic power; the turnover 
number kES is > 10
4 sec-1 (Rosenberry 1975), which is one of the highest turnover 
numbers reported for enzyme catalysis.  Moreover, for the natural substrate ACh, kE is > 
108 M-1 sec-1 (Rosenberry and Bernhard 1971; Rosenberry 1975) and thus the diffusion 
of ACh to the AChE active site is possibly rate determining.  The high second  
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order rate constant indicates that AChE is one of the evolutionary perfect enzymes.  
Table 1.1 shows the substrate specificity of AChE in terms of the kE, a steady state 
kinetic parameter representing the conversion of free enzyme and free substrate to a 
transition state(s) in the acylation stage of catalysis, and Km, the concentration of 
substrate to reach Vmax/2 rate.  It is revealed from Table 1.1 that AChE shows more 
specificity towards ACh, ATCh, and acetylselenocholine compared to other esters. 
From kinetic (Nachmansohn and Wilson 1951), fluorescence (Rosenberry et al. 
2008), and X-ray crystallographic data (Sussman et al. 1991), it has been established that 
AChE catalysis is not as simple as shown in Scheme 1.  It has been shown that the 
catalytic mechanism of AChE depends upon the binding of substrate not only at the acyl-
binding site (A-site) but also at the P-site (discussed in detail in the next section).  
Considering the involvement of P-site, Rosenberry (Rosenberry 2010) has proposed an 
alternative mechanism (Scheme 2) of AChE catalysis, which is considered an extended 
version of classical Michaelis-Menten model for AChE-catalyzed substrate hydrolysis.  
In Scheme 2, the initial enzyme–substrate complex (ES) converts to an acylated enzyme 
intermediate (EA), which is then hydrolyzed to give product (P).  The scheme includes 
two additional intermediates on the catalytic pathway, an initial complex with substrate 
bound to the P-site (ESP) and an intermediate EAP between ES and EA.  In EAP, the 
enzyme has been acylated but the product P has not yet dissociated from the A-site.  
Moreover, the scheme considers certain ternary complexes, in which the intermediate 
also binds substrate at the P-site (ESSP, EAPSP, and EASP).  This makes the rate 
constants for inter conversion of the intermediates to the next to be changed  
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Table 1.1:  Substrate specificity of Human AChE. 
Substrate kE (M
-1
.s
-1
) Km (mM) 
Acetylcholine (ACh)a 1.00 x 108 0.046 
Acetylthiocholine 
(ATCh)b 
1.58 x 108 0.040 
Acetylselenocholine 
(ASeCh)c 
3.62 x 108 0.020 
Acetylazacholine 
(AACh)d 
2.50 x 103 2.00 
Ethyl acetatea, 7.90 x 101 N.A 
Phenyl acetatea, d 5.00 x 106 N.A 
N. A = Not applicable. 
a (Rosenberry 1975); b (Froede and Wilson 1984); c (Moore and Hess 1975); (Moore and 
Hess 1975)d(Hillman and Mautner 1970) 
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Scheme 2:  Extended model for substrate hydrolysis by AChE.  E = AChE, S = 
substrate, EA = acyl-enzyme, P = product, ESP.= initial complex where substrate bound 
to peripheral binding site (P-site), EAP = an intermediate between ES and EA, where the 
enzyme is acylated but the P is not yet dissociated from the complex, all ks represent the 
rate constants and the Ks represents the equilibrium constants.  iKs are the equilibrium 
constants which represent the equilibrium between the enzyme-substrate initial complex 
and another substrate molecule, this constant represents the inhibition situation when a 
already bound substrate inhibits the incoming substrate to bind and involves in catalysis. 
Adapted from (Rosenberry 2010) 
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in these ternary complexes by the relative factors a, g, and b respectively.  The most 
important aspect of this scheme is the substrate trapping by P-site.  The P-site transiently 
binds the substrate before it forms the ES complex, and confirms that most of the 
substrates which come across the P-site end up to the A-site for catalysis (Szegletes et al. 
1999; Mallender et al. 2000; Johnson et al. 2003).  In this way, the low affinity P-site 
highly contributes towards the catalytic efficiency of the AChE active site.  However, the 
initial binding of substrate at P-site poses a substantial threat for catalytic efficiency at 
high concentration of substrate, most of the time this condition leads to the „steric 
blockade‟ (Szegletes et al. 1999).   
1.3  Inhibitors of AChE: 
As discussed above, AChE is utilized as a drug target in Alzheimer‟s diseases 
(AD), glaucoma, and myasthenia gravis because of its role in hydrolyzing ACh in active 
neurons (Millard and Broomfield 1995).  In neuronal diseases, the patient suffers from 
memory loss that occurs due to the destruction of neurons.  In this condition, the ailing 
neuron produces less ACh and hinders the normal process of neuron to neuron 
information transfer, which ultimately leads to severe memory loss.  In this abnormal 
situation, if the hydrolysis of ACh by AChE occurs normally then the concentration of 
ACh at the synapse (Fig. 1.4) decreases and the process of information transfer is 
compromised.  Researchers have proposed that AChE can be targeted to control this 
abnormality (Parnetti 1995; Taylor 1998; Cutler and Sramek 2001).  Inhibition of AChE 
will decrease the ACh hydrolysis rate, as a result the concentration of ACh at the synapse 
will remain nearly constant and preserve the normal process of information transfer.  For 
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the last 30 years, several inhibitors have been synthesized for AChE.  Some of them are 
reversible and most of them are irreversible inhibitors. 
It has always been a point of discussion among scientists whether reversible or 
irreversible inhibitors are more effective for controlling abnormal memory loss in 
patients (Taylor 1998).  A large number of scientists think that reversible inhibitors are 
suitable drug candidates because they can be easily excreted from the body upon excess 
use of fluid, which leads to fewer side effects .   
1.3.1 Reversible inhibitor of AChE: 
There are a large number of reversible inhibitors of AChE available on the 
market.  Most of them are laboratory synthesized and specifically designed for the AChE 
active site.  The inhibitors are designed in such a way that they can specifically target the 
P-site and/or CAS in AChE active site (Kryger et al. 1999; Bourne et al. 2003; Alonso et 
al. 2005; Johnson and Moore 2006).  The reversible inhibitors extensively used in AChE 
inhibition studies as well as neuronal disease drugs include physostigmine, neostigmine, 
rivastigmine, donepezil, tacrine, and huperzine (Fig. 1.8).  The IC50s of these compounds 
against human AChE are in the low nM range (Lahiri et al. 2004; Eckert et al. 2006; 
Belluti et al. 2009).  In some of the inhibitors (neostigmine, tacrine) a positively charged 
quaternary N-atom has been introduced to facilitate the substrate like π-cation interaction 
with the anionic site (Pauling and Petcher 1971; Harel et al. 1993).  On the other hand, 
some of them contain aromatic substitutions that facilitate the π-π interaction with the P-
site and CAS aromatic residues (Harel et al. 1993).  Inhibitors like propidium, which has 
a phenanthrene-like aromatic moiety linked with choline by a carbon chain 
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Fig. 1.8:  Reversible inhibitors of AChE.  a) Physostigmine, b) Neostigmine, c) 
Rivastigmine, d) Donepezil (AriceptTM), e) Tacrine (CognexTM), and f) Huperzine.  
Except huperzine (a sesquiterpene, isolated from a plant called Huperzia Serratta), all the 
compounds are laboratory synthesized.  Mostly, these inhibitors bind to the P-site and/or 
CAS site of the AChE active site.  Among all the inhibitors shown, only donepezil and 
tacrine are approved as drugs for AD. 
a) b) c) 
d) e) 
f) 
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 linker, can bind simultaneously to the P-site and CAS site at the AChE active site (Radic 
et al. 2008).  Such a compound can arrest the internal dynamics of the AChE active site 
and stabilize the inactive form of the enzyme.  To date, donepezil (AriceptTM) and tacrine 
(CognexTM), which are very efficient AChE reversible inhibitors, have been approved as 
drugs for AD.  
1.3.2 Organophosphates as irreversible inhibitors of AChE: 
Organophosphates (OPs) act as a pseudo-substrate for SHs.  This class of 
compounds have been widely used as SH inhibitors (Kam et al. 1993; Glynn et al. 1994; 
Winkler et al. 1996).  The rate of hydrolysis of the natural substrate is reduced (generally 
several orders of magnitude) when OPs phosphorylate the SHs.  It is well established in 
the literature that OPs covalently modify the active site nucleophilic serine of SHs and 
irreversibly inhibit the enzymes (Harel et al. 1991; Glynn et al. 1994; Winkler et al. 
1996; Chambers and Oppenheimer 2004).  OPs, like diisopropylfluorophosphate (DIFP) 
have been used as activity-based probes (ABP) to characterize the SH family members 
(Liu et al. 1999; Kidd et al. 2001).  Besides, DIFP, other OPs like diethylfluorophosphate 
(DEFP), paraoxon, tabun, soman, and VX (Fig. 1.9) are extensively used in the literature 
for SH characterization and inhibition studies.   
OPs exhibit two important features that are used for global characterization of 
SHs (Fig. 1.10).  First, OPs use several conserved features of the SH active site, 
including a highly nucleophilic serine O-atom (susceptible to the reaction with highly 
electrophilic P-atom of OP) and the oxyanion hole which stabilizes the SH-substrate  
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Figure 1.9:  Organophosphate inhibitors of SHs.  a) Diisopropylfluorophosphate 
(DIFP), b) Diethylfluorophosphate (DEFP), c) Tabun, d) Soman, e) VX, and f) Paraoxon.  
Though these OPs are mainly designed to inhibit acetylcholinesterase (AChE) and 
butyrylcholinesterase (BuChE), other SHs like lipases and some other proteases are also 
inhibited by them (Casida and Quistad 2004; Casida et al. 2008). These classes of 
compounds are considered as nerve agents because they target the AChE at cholinergic 
neurons to prevent the same to reach the resting state. 
a) b) c) d) 
e) f) 
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Figure 1.10:  Formation of tetrahedral intermediate in the reaction between SH and 
OP.  SH – OP reaction occurs through the formation of tetrahedral intermediate similar 
to the intermediate that forms when SH reacts with its natural substrate.  The 
intermediate has an anionic character and can be stabilized by oxyanion hole forming 
peptidic NH-group of glutamic acid and alanine in the SH active site.  The similarity of 
the intermediate structure of SH-OP complex and SH-substrate complex has been 
utilized to design mechanism-based OP inhibitor against SH. 
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tetrahedral intermediate (resembled by similar tetrahedral structure of OPs) (Fig. 1.10) to 
attain high target selectivity of SH class of enzymes.  Second, OPs exhibit extremely low 
cross-reactivity with other classes of hydrolases, including aspartyl-, cysteinyl-, and 
metallo-hydrolases (Bouma et al. 1980).   
Organophosphates (OPs) or phosphonates are extensively used as AChE 
irreversible inhibitors.  As mentioned above, this class of compounds covalently modifies 
the AChE active site by reacting with the active site serine.  The tetrahedral intermediate 
of the AChE–OP complex is very similar to the AChE–ACh complex which is stabilized 
by the oxyanion hole forming residues (Fig. 1.10).  Soman, VX, sarin, and DIFP (Fig. 
1.9) are efficient irreversible inhibitors for AChE.  They have low nM IC50s against 
human AChE (Worek et al. 2004).  Their bimolecular rates of inactivation (ki) are in the 
range of 105–108 M-1 min-1, which tags them as highly efficient inactivators of AChE.  
Even though the AChE-OP reaction has been shown to be a purely irreversible type, 
reactivation of AChE can occur (~0.02 min-1) (Aldridge and Reiner 1969; Sultatos 1994; 
Worek et al. 2004), provided the process of aging has not occurred.  Aging is one of the 
poorly understood reactions in which one alkoxy substituent of OP is hydrolyzed, leaving 
the mono-alkoxy phosphate bound irreversibly to the active site serine of AChE (Sultatos 
1994)  The process of aging is more likely when the alkyl substituent of the alkoxy group 
of OP has more than two carbon atoms.  In the absence of aging, the phosphorylation of 
AChE by OPs is often kinetically described as a Ping Pong Bi Bi reaction that reduces to 
Ordered Uni Bi reaction when the second substrate, water, is present in excess (Segel 
1975). 
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Researchers have extensively used OPs to probe and to characterize the AChE 
active site structure (Liu et al. 1999; Kidd et al. 2001; Patricelli et al. 2001).  Barak et. al. 
first proposed that covalent modification at the active site serine by DIFP led to an 
allosteric conformation change at P-site Trp286 and Tyr133 which ultimately led to an 
altered binding of P-site binding ligands like propidium and edrophonium (Barak et al. 
1995).  This was the first evidence of allostery in AChE active site. 
OPs can cause neurotoxic syndrome (NS) in human and other animals.  One of 
the well characterized and fatal NSs is caused by the inhibition of acetylcholinesterase 
(AChE) at cholinergic synapses (Glynn 1999).  However, it has been reported that proper 
dosage of OPs can prevent several neuronal disease conditions like AD (Taylor 1998).  
The above mentioned neurotoxic property of OPs have been deliberately used to target 
insect neuronal system for the development of pesticides (Weill et al. 2002; Pang 2006).   
The search for an efficient natural product inhibitor of AChE is ongoing owing to 
an increase in life expectancy of human population, increased incidence of neuronal 
disorder diseases like AD, glaucoma, and other clinical interests.  To date, several natural 
product inhibitors of AChE have been reported; most of them are alkaloid (huperzine, 
amaryllidaceae), carbamate (physostigmine), or peptide-based (fasciculin) (Hostettmann 
et al 2006; (Bourne et al. 1995).  The only phosphate-based natural product inhibitor of 
AChE reported in the literature is cyclophostin (Kurokawa et al. 1993) (Table 1.2 and 
Table 3.1 in Chapter III).  Kurokawa et. al. (A) first isolated this compound from the 
NK901093-70 strain of bacterium Streptomyces  
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Table 1.2:  Cyclophostin and its cyclic phosphonate analogs. 
 
 
 
 
 
 
 
 
a(Kurokawa et al. 1993); b(Bandyopadhyay et al. 2008); c (Kurokawa et al. 1993; Dutta et 
al.). 
Name Structure 
Cyclophostina 
 
Phosphonate analog of 
Cyclophostin b, c 
 
Mono cyclic phosphonates 
analog of Cyclophostinb, c 
 
1 
2 
3 4 
5 
6 
7 8 
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lavendulae and characterized it as a bicyclic phosphate containing seven membered 
phosphate ring fused with five membered lactone ring.  The compound was reported to 
exhibit the IC50 of 8 e-4 µM against grasshopper AChE (Kurokawa et al. 1993).  
Although the biosynthetic pathway for the synthesis of cyclophostin or the function of 
the metabolite in Streptomyces lavendulae is still unknown, cyclophostin has gathered a 
lot of importance due to its highly efficient inhibition of AChE.  Due to extremely low 
yield from the natural source, organic synthetic chemists have taken the challenge to 
synthesize this bicyclic entity.  Kurokawa et al. (1993) did not report the exact 
mechanism of action of cyclophostin against AChE.  In this study, we have reported the 
mode of action of cyclophosphonate analogs of cyclophostin (Table 1.2 and Table 3.1) 
and some diastereoisomers of cyclophostin (Table 3.3) against human, electric eel and 
house fly AChE. 
1.4  Introduction to Hormone-sensitive lipase (HSL): 
1.4.1  General background: 
Free fatty acids (FFAs) are the main source of energy for most mammalian cells 
and tissues.  The majority of the FFAs found in plasma originate from the adipose tissue 
where the FFA is stored as triglycerides (TGs).  Up to 150 g of fatty acids, which 
corresponds to nearly half of the daily caloric need, can be obtained from adipose tissue 
(Holm et al. 2000; Yeaman 2004).  TG hydrolysis occurs through three consecutive 
reaction steps and is catalyzed by three extremely important metabolic enzymes: 
triacylglyceride lipase (TGL), hormone-sensitive lipase (HSL) and monoglyceride lipase 
(MGL).  TGL hydrolyzes the TGs and MGL hydrolyzes the (monoacylgylcerides) MGs, 
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whereas HSL has broad substrate specificity and can catalyze the hydrolysis of TGs (Fig. 
1.11), diglycerides (DGs), monoacylglycerides (MGs), cholesteryl esters (Fig. 1.11) as 
well as retinyl esters (Kraemer and Shen 2002).  Its activity towards diglycerides is 10 
and 5 fold higher than that toward tri- and monoacylglycerides (Kraemer and Shen 
2002).  Moreover, the hydrolysis of TGs and DGs, but not the DGs, is a c-AMP 
dependent protein kinase A (PKA) mediated phosphorylation dependent.  HSL is not 
known to show any phospholipase activity (Kraemer and Shen 2002).   
Initially it was believed that HSL is an intracellular adipocyte-specific 
triacylglycerol lipase but now it has been shown that HSL is expressed in multiple other 
locations, including macrophages, pancreatic β-cells, corpus luteum (steroidogenic 
tissue), and intestinal mucosa (Cook et al. 1982; Grober et al. 2003). 
Due to HSL‟s broad lipid substrate specificity, it exhibits multiple functions in 
lipid metabolism (Table 1.3).  HSL activity is regulated by several mechanisms, 
including reversible phosphorylation by different types of protein kinases, interaction 
with different protein partners, and translocation to different locations within the 
adipocyte cell (Stralfors and Belfrage 1983; Osterlund et al. 1999; Su et al. 2003; 
Sztalryd et al. 2003).  It is believed that altered expression of HSL in different cells and 
tissues may be linked with numerous pathological states, including type II diabetes, 
obesity, and atherosclerosis (discussed in section e) (Ylitalo et al. 2000; Hoffstedt et al. 
2001; Teruel et al. 2005; Palou et al. 2009).   
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Fig. 1.11:  Hydrolysis of triacylglycerol (TAG) and cholesterol ester (CE) by HSL.  
HSL hydrolyzes the ester function both at TAG and CE to produce fatty acid and 
glycerol or cholesterol respectively.  The TAG hydrolysis generally happens in adipose 
tissues and the CE hydrolysis occurs in macrophages.   
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Table. 1.3:  Expression and function of HSL at different tissues and cell types 
a
. 
Cell type Major product Main function 
Adipocyte Fatty acid Export for oxidation 
Muscle Fatty acid Oxidation 
Pancreatic β-cells Fatty acid Signal transduction 
Macrophage Cholesterol Export via high density 
lipoprotein (HDL) 
aAdapted from (Yeaman 2004). 
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1.4.2  Structure of and biochemical properties of HSL: 
After cDNA cloning of HSL, it was revealed that the enzyme has low sequence 
homology with other mammalian lipases (Holm et al. 1988; Holm et al. 1988).  
However, HSL, having 775 amino acids, showed better sequence identity with the lipase 
from the bacteria called Moraxella TA 144 (Feller et al. 1991; Langin et al. 1993).  
Moreover, sequence similarity was found with several other bacterial lipases, 
acetylcholinesterase (AChE), and lipoprotein lipase (LPL) which led to the idea that it 
belongs to the lipase/esterase super family of enzymes (Hemila et al. 1994).   
HSL is a serine hydrolase (SH) and can be inhibited by common SH inhibitor 
diisopropylfluorophosphate (DIFP) (Fredrikson et al. 1981).  It contains the Gly-X-Ser-
X-Gly motif, having an active site serine that is found in other SH family members 
(Cook et al. 1981; Holm et al. 1988).  The studies also identified the catalytic triad 
residues as Ser423, Asp703, and His 733 in the rat HSL amino acid sequence (Fig. 
1.12A) (Hemila et al. 1994; Holm et al. 1994).  Sequence analyses, limited proteolytic 
digestions and molecular modeling studies revealed a multi domain structure for HSL 
(Fig. 1.12B).  The first 300 amino acids constitute the N-terminal domain and the rest of 
300-767 amino acids constitute the C-terminal domain that includes the regulatory loop 
having 150 amino acids (Hemila et al. 1994; Contreras et al. 1996).  The N-terminal 
domain, which does not have any similarity with other proteins or peptides, is proposed 
to be a docking domain for HSL-interacting protein partners and also involved in „nose 
to tail‟ dimerization of the protein (Osterlund et al. 1996; Osterlund et al. 1999).  It is 
shown that the fatty acid binding protein-4 (FABP-4) docks at the N-terminal  
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A 
 
   Primary structure of rat HSL 
B 
 
    Domain structure of rat HSL 
Fig. 1.12:  Predicted structure of rat HSL.  A)  Primary structure of HSL:  Orange, 
violet, and yellow blocks represent the N-terminal domain, C-terminal domain, and 
regulatory loop domain amino acid sequences respectively.  The catalytic residues are 
indicated as Ser423, Asp703, and His733.  Probable phosphorylation sites at regulatory 
loop domain are Ser563, Ser565, Ser659, and Ser660 (Yeaman 2004).  B)  Domain 
structure of HSL:  The color coding is the same as A).  The N-terminal domain (33 kD) 
is composed of 300 amino acids, whereas the C-terminal domain (48kD) is composed of 
467 amino acids.  The regulatory module (16.5 kD) is a part of the C-terminal domain 
having 150 amino acids (residues 521 to 669).  The N-terminal and C-terminal domain is 
connected by a hinge region that is composed of 20 amino acids (315-335) (black line).  
Adapted from (Holm et al. 1988; Yeaman 2004). 
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domain of the HSL and regulates product inhibition by opening up the product release 
door at the C-terminal domain (Osterlund et al. 1999; Kraemer and Shen 2002; Jenkins-
Kruchten et al. 2003; Ali et al. 2005). 
Molecular modeling studies revealed that HSL contains an α/β-hydrolase fold at 
the C-terminal domain and the regulatory loop domain runs from residue 521 to 669 
between α26,7 and α
4
6,7 (Fig. 1.13 ) (Contreras et al. 1996; Osterlund et al. 1996) in the 
same domain.  The regulatory domain of HSL is a unique structural component that 
contains several phosphorylation sites and is only found in this enzyme.  To date no other 
lipase is known that is regulated by phosphorylation; it is still an outstanding question 
how the phosphorylation of serine residues in the regulatory domain controls the intrinsic 
activity of HSL catalytic domain, manages the interaction with different substrates and 
products, and regulates the translocation of the enzyme to and from the lipid droplets.  It 
has been speculated that the regulatory domain of HSL is actually an evolutionary 
modification of lid domain found in other lipases like Candida rugosa lipase and human 
pancreatic lipase (Brocca et al. 2003; Passolunghi et al. 2003).  But having no homology 
with lid domain amino acid sequence and with other proteins or peptides, the idea of the 
regulatory loop being a modified lid has been discarded.  The loop has three helical 
regions (Fig. 1.14); the most important region is the one which contains the 563 and 565 
phosphorylation sites.  It is proposed that upon phosphorylation the distortion of the 
helical structure occurs, which ultimately leads to a global conformational change which 
in turn triggers the translocation of the HSL to the lipid droplets (Contreras et al. 1996; 
Ben Ali et al. 2004). 
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Fig. 1.13:  Secondary structure of C-terminal domain of rat HSL.  The secondary 
structure of the C-terminal domain of rat HSL contains α/β-hydrolase fold which consists 
of 8 α-helices (rectangular boxes) and 7 β-sheets (black arrows) in alternate manner.  
This unique α/β-hydrolase fold structure brings the Ser423, Asp703 and His733 in 
proximity to create the catalytic triad for catalysis.  Catalytic Ser423 is located between 
β5 and α5,6, whereas, other catalytic triad residues Asp703 and His733 are located at β7/α
4 
7,8 and β8/α
2
8 junctions, respectively.  The red box represents the regulatory region which 
is located between α26,7 and α
4
6,7, and contains the phosphorylation sites S563, S565, 
S659, and S660 (Contreras et al. 1996). 
Adapted from (Contreras et al. 1996). 
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Fig. 1.14:  Predicted secondary structure of regulatory loop domain.  The amino acid 
sequence of the regulatory loop domain (521-669) has been fed to the Hierarchical 
Neural Network method (HNN) freeware tool and the predicted secondary structure has 
been obtained.  The blue bars represent the α-helical region, whereas the red and purple 
bars represent β-sheets and random coil respectively.  In the structure, there are three 
distinct -helical regions α1, α2, and α3.  Among them α2 contains the basal and regulatory 
phosphorylation sites S563 and S565.   
α3 α1  α2  
36 
 
As discussed above, HSL hydrolyzes the lipid substrate with broad substrate 
specificity.  It is shown that HSL prefers sn 1-ester and 3-ester bonds when it hydrolyzes 
the triacylglycerol (Fredrikson and Belfrage 1983).  It is reported that HSL does not have 
preference for the fatty acid in the triacylglycerol; it shows increasing activity with 
decreasing chain length of the fatty acid group (Raclot et al. 2001).  Moreover, HSL is 
active against short chain esters like, p-nitro phenyl butyrate, vinyl acetate, vinyl 
propionate in vitro.  Activity of the enzyme against these compounds is retained even 
after lipase activity is destroyed by limited proteolysis (Smith et al. 1996).  This 
phenomenon indicates to the fact that for lipase activity, HSL needs to have properly 
aligned hydrophobic acyl chain binding site/s that is not essential for short chain ester 
binding and hydrolysis.   
1.4.3  Phosphorylation of HSL: 
As mentioned above, the most important feature of HSL is its regulation by 
phosphorylation, induced by β-adrenergic receptor agonists or hormones.  It is seen that 
the HSL lipolysis of triacylglycerol can be enhanced up to 2-fold upon hormone induced 
c-AMP-dependent protein kinase phosphorylation in vitro (Fredrikson et al. 1981; Cook 
et al. 1982).  The same trend for other short chain substrates has not been seen yet but it 
is reported that cholesteryl ester hydrolysis can also be enhanced by phosphorylation of 
HSL (Cook et al. 1982; Cook et al. 1983; Greenberg et al. 2001).  It is possible that for 
short chain substrate, the assay condition is not sensitive enough to detect those changes. 
Mutational studies and structural analysis have revealed that there are four 
distinct c-AMP-dependent protein kinase sites in HSL regulatory domain: Ser563, 
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Ser565, Ser659, and Ser660 (Stralfors and Belfrage 1983; Stralfors et al. 1984; 
Anthonsen et al. 1998).  Ser565 is considered as the basal phosphorylation site and 
Ser563 as regulatory phosphorylation site.  It is proposed that Ser565 phosphorylation 
site prevents the regulatory site Ser563 from being phosphorylated and thwarts the HSL 
lipolysis of lipid droplets (Vossler et al. 1997; Shen et al. 1998; Zhang et al. 2003).  
Thus, Ser565 is sometimes considered to be an anti-lipolysis regulation element in HSL.  
There is strong evidence that Ser565 is phosphorylated exclusively by cAMP-dependent 
protein kinase in vivo but in vitro this site can be phosphorylated by several other kinases 
too (Garton et al. 1989; Moore et al. 2005; Watt et al. 2006; Krintel et al. 2009).  
Mutations at Ser563 and Ser565 to alanine do not completely abolish the cAMP-
dependent phosphorylation and in turn the activation of HSL; this data suggests that 
Ser660 and Ser659 also play a vital role in phosphorylation-induced activation of HSL 
(Anthonsen et al. 1998; Su et al. 2003; Krintel et al. 2008).  Recently, it has been 
established that phosphorylation at Ser649 and Ser650 in human HSL (corresponding to 
Ser659 and Ser660 in rat HSL) is the major determinant of lipolytic activity of the 
enzyme in vitro, but they have less contribution in non-lipolytic activity under non-
phosphorylated condition (Krintel et al. 2008).  Moreover, the cAMP-dependent pathway 
activates mitogen-activated protein kinase (MAPK) and extra-cellular signal-regulated 
protein kinase (ERK) that can phosphorylate the Ser600 site and can enhance the activity 
of HSL almost 2-fold (Garton et al. 1989; Greenberg et al. 2001; Donsmark et al. 2004). 
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1.4.4  Phosphorylation induced translocation of HSL: 
As mentioned above, the lipolytic activity of the HSL increases up to 2-3 fold in 
vitro upon phosphorylation.  On the contrary, it has been established that the lipolytic 
rate increases up to 100 fold when tested in rat adipose cells (Nilsson et al. 1980; Londos 
et al. 1985; Grober et al. 1997).  This discrepancy in lipolytic rate happens mostly due to 
the involvement of other protein/s.  The most important one is the hydrophobic lipid 
coating protein, perilipin.  Perilipin is one of the most abundant adipocyte lipid binding 
proteins that binds the surface of lipid droplets and regulates lipolysis (Londos et al. 
1999; Londos et al. 1999).  It is established that perilipin forms a barrier for HSL so that 
non-phosphorylated enzyme cannot perform lipolysis (Brasaemle et al. 2000; Brasaemle 
et al. 2009; Wang et al. 2009).  Under basal conditions, HSL stays in the cytoplasm and 
perilipin protects the lipid droplets by forming a protein coat (Wang et al. 2009).  It has 
been shown that HSL physically interacts with the N-terminal domain of perilipin (Shen 
et al. 1999; Wang et al. 2009) in vivo.  However, this is not the sole factor that prevents 
non-stimulated HSL from translocating to the lipid droplets; binding of perilipin to other 
protein partners like α/β-hydrolase fold containing protein 5 (Abdh5) also contributes to 
form the barrier (Yamaguchi; Granneman et al. 2007; Granneman et al. 2009).  Upon 
catecholamine-induced phosphorylation (mainly the cAMP-dependent pathway), HSL 
translocates to the lipid droplets and at the same time phosphorylated perilipin leaves the 
lipid droplet surface, thus facilitating the access of HSL to the lipid droplets (Fig. 1.15).  
It is also proposed that perilipin induces a structural change in the lipid droplet by 
breaking it into small droplets so that the total accessible surface area increases 
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Fig. 1.15:  Phosphorylation and translocation of HSL to lipid droplets.  The picture 
shows the common mechanism of phosphorylation and translocation of HSL to the lipid 
droplets in adipocyte tissue.  Under basal conditions, the non-phosphorylated HSL 
resides in the cytoplasm and the lipid droplets are well protected by the lipid-coat protein 
perilipin.  After hormone induction, HSL and perilipin both get phosphorylated mainly 
by cAMP-dependent protein kinase-A.  Due to phosphorylation, perilipin releases the 
barrier around the lipid droplets and divides the bigger lipid droplet into smaller droplets 
so that the overall accessible surface area of the droplets increases (Sztalryd et al. 2003; 
Shen et al. 2009).  HSL translocates from the cytoplasm to the droplet surface and does 
the hydrolysis of lipid. 
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(Su et al. 2003; Marcinkiewicz et al. 2006).  Mutagenesis studies have confirmed that 
simultaneous phosphorylation of both HSL and perilipin is required to perform 
successful translocation and lipolysis of HSL (Su et al. 2003; Sztalryd et al. 2003; Shen 
et al. 2009).   
As mentioned above, HSL is primarily a cytosolic enzyme under basal 
conditions.  It has been shown both in vitro and in vivo that hormone-induced 
phosphorylation triggers the translocation of HSL to the hydrophobic lipid droplets (Su 
et al. 2003; Miyoshi et al. 2006; Martin et al. 2009).  It has been proposed that a major 
conformational change triggers the translocation of HSL upon phosphorylation (Holm et 
al. 1988).  Many scientists have proposed that the phosphorylation primarily leads to 
some sort of electrostatic interaction that ultimately induces the exposure of hydrophobic 
surface area (Holm et al. 1988; Anthonsen et al. 1998).  C Holm et al.(1988) has long 
been proposed that an eight amino acid hydrophobic patch (F734LSLAALC741) at the C-
terminal domain of the rat HSL (Fig. 1.16) might be involved in the exposure process 
(Holm et al. 1988; Krintel et al. 2009).  Recently, it has been shown that the 
conformational change is indeed a form of hydrophobic surface exposure of the enzyme 
(Krintel et al. 2009).  This is one of the phenomena under investigation in this 
dissertation. 
Even though the in vitro studies have elucidated most of the complicated 
phosphorylation related regulation of HSL, the mechanism of regulation of HSL activity 
in vivo is not that simple.  Recently it has been shown that not only cAMP-dependent or 
independent pathways regulate HSL, but there are numerous other protein partners like 
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Fig. 1.16:  Kyte and Doolittle hydropathy plot of rat HSL primary sequence.  The rat 
HSL primary sequence has been fed to the freeware tool of Kyte and Doolittle 
hydropathy region predictor (Kyte and Doolittle 1982).  The parameter sets are followed: 
amino acid window size: 9; weight variation model: linear; relative weight of the window 
edges compared to window center: 100.  Apart from the hydrophobic acyl-binding site 
(ABS) (residue 442-453) predicted by the modeling studies (secondary structure aided 
multiple sequence alignment of rat HSL using Candida rugosa lipase as template), the 
plot predicted an additional lipid binding patch from F734-C741.  C Holm et al. (1988) 
proposed that this patch might play a vital role in phosphorylation induced translocation 
of HSL to the lipid droplets (Holm et al. 1988; Krintel et al. 2009).   
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 fatty acid binding protein (FABP) (Holm et al. 2000), lipotransin (Syu and Saltiel 1999), 
and vimentin (Shen et al. 2009; Shen et al.) which physically interact with the enzyme 
and play a vital role in regulating HSL‟s activation and translocation. 
1.4.5  HSL as potential drug target for diabetes type –II: 
It is well established in the literature that insulin exerts anti-lipolytic activity by 
activating phosphodiesterase and modulating the cAMP-dependent pathway (Kitamura et 
al. 1999; Rondinone et al. 2000; Hasegawa et al. 2002).  In addition, insulin also 
activates the ERK signaling pathway; so it is of great debate whether insulin‟s main role 
is to induce phosphorylation or dephosphorylation of Ser600 (Londos et al. 1985).  It is 
proposed that insulin‟s action has both cAMP-dependent and cAMP-independent 
components; it is highly probable that in addition to phosphodiesterase activation, it 
might induce the phosphorylation of phosphatases and ultimately regulate the anti-
lipolytic activity of HSL (Stralfors and Honnor 1989; Resjo et al. 2002).  It has been 
observed in adipocyte tissues in vivo and in vitro that phosphatases, like protein-
phosphatase-2A (PP2A), protein-phosphatase-2C (PP2C), and protein-phosphatase-1 
(PP1), do dephosphorylate at least at the Ser563 site (Wood et al. 1993; Clifford et al. 
1998) of HSL.   
Insulin regulates lipid hydrolysis by binding to the insulin receptor and by 
activating the PDE3B enzyme to minimize the cAMP-dependent protein kinase-A action 
(Nilsson et al. 1980; Londos et al. 1985; Rondinone et al. 2000).  It is a well established 
fact that diabetes type-II patients suffer from insulin resistance state in which the normal 
secretion of insulin becomes inadequate to exert insulin response in liver, muscle and 
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adipocyte cells (Hotamisligil et al. 1995; Groop et al. 1996; Gonzalez-Sanchez and 
Serrano-Rios 2007).  Under these conditions, the triacylglycerol hydrolysis increases and 
ultimately hinders the process of glucose storage in liver and uptake in muscles.  In this 
way the concentration of glucose increases in the blood and patients suffer from acute 
type-II diabetes disease condition.  To help control this, scientists have proposed to 
inhibit the activity of HSL to minimize the triacylglycerol hydrolysis and ultimately to 
manage the increasing glucose content in the blood (Reynisdottir et al. 1995; Ylitalo et 
al. 2000; Claus et al. 2005).  Scientists have also noticed an altered mRNA expression 
level of HSL in diabetic and obese patients in vivo (Klannemark et al. 1998; Smih et al. 
2002).  This gives an additional support for the involvement of HSL in obesity and 
diabetes disease conditions.   
1.5  Inhibitors of HSL: 
According to the American Diabetes Association estimation in 2009, about 20 
million people alone in North America have been diagnosed with diabetes and among 
90% of them have been affected by diabetes type-II.  As discussed above, HSL being a 
potential diabetes type-II drug target, it has become important to find a potent HSL 
inhibitor.  As the three dimensional structure of HSL has not been established, the high 
throughput screening of laboratory-synthesized compound libraries against HSL has been 
a usual method for finding potent inhibitors.  To date, several potential HSL inhibitors 
have been synthesized and characterized.  Most are carbazate, pyrrolopyrazinedione, 
oxadiazolone (compound 7600), and urea-based laboratory synthesized compounds.  As  
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shown in Table. 1.4, the carbazate, pyrrolopyrazinedione-based compounds, and 
compound 7600 are most potent (IC50 in lower nM range) inhibitors of HSL (Slee et al. 
2003; de Jong et al. 2004; Ben Ali et al. 2006).  From the sequence similarity of 
Alicyclobacillus acidocaldarius esterase with the HSL C-terminal domain and the mass 
spectroscopic data available for esterase-compound 7600 complex, it is proposed that 
HSL‟s active site serine O-atom either attacks the ester carboxylic C-atom present in the 
molecules (carbazates) or opens the oxadiazolone ring (compound 7600) to covalently 
modify its active site (Claus et al. 2005; Ben Ali et al. 2006).  It is speculated that the 
additional aromatic substitutions in the inhibitors (carbazate, pyrrolopyrazinedione, 
oxadiazolone) facilitate the initial binding of the inhibitor to the active site hydrophobic 
residues of HSL (Ben Ali et al. 2006).  To date, no reversible inhibitor (binder) has been 
reported for HSL except BAY (Table. 1.4) which showed surprising reversible character, 
having a time-dependent inactivation mechanism against the enzyme (Claus et al. 2005). 
Apart from laboratory synthesized inhibitors, the search is still on to find a 
natural product inhibitor for HSL.  Vertesy et. al., first reported a natural product 
inhibitor of HSL, cyclipostin (Table. 1.5), that was isolated from the fermentation 
product of Streptomyces species DSM 13381 (Vertesy et al. 2002).  They reported the 
isolation of several analogs of this compound having the IC50s against rat adipocyte HSL 
in low nM range (Vertesy et al. 2002).  The exact mechanism of action of these 
compounds against HSL has not yet been reported.  As shown in Table. 1.5, the core 
structure of the cyclipostin is identical to the AChE inhibitor cyclophostin, having long  
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Table. 1.4:  Inhibitors of human HSL and their IC50s. 
Class of compound 
Commercial 
Name 
Structure 
IC50 (nM) 
Esterase 
assay 
Lipase 
assay 
Carbazatesa N.A. 
 
N.D. 19 
Pyrrolopyrazinedioneb N.A. 
 
120 180 
Oxadiazolonec 
Compound 
7600 
 
N.D. 60 
Isoxazononyl uread BAY 
 
N.D. 5 
IC50s are against human HSL; N.A.- Not Applicable; N.D.- Not determined. 
a(de Jong et al. 2004); b(Slee et al. 2003); c(Ben Ali et al. 2006); d(Claus et al. 2005). 
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Table. 1.5:  Structures of analogs of cyclipostin and their potency against rat HSL
a
. 
Core Structure 
of Cyclipostin 
Analogs 
IC50 (nM) 
Name R` R`` 
 A  CH3 20 
P  CH3 30 
P2  CH3 40 
S  CH2CH3 20 
aAdapted from (Vertesy et al. 2002) 
OH
10
13
12
13
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oxy-alkyl chain attached to the central P-atom.  This makes the structure highly suitable 
for the hydrophobic HSL active site.  In addition to the long C-chain substitutions, these 
compounds have a highly reactive seven-membered phosphate ring that can covalently 
modify the active site serine residue (very similar to the modification mentioned in 
AChE active site in Chapter III).   
One of the goals of this dissertation is to test different phosphonates analogs 
(Chapter IV) of cyclipostin against rat HSL and determine the mechanism of inhibition. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1  Inhibition studies of acetylcholinesterase (AChE): 
Acetylcholinesterase (AChE) from electric eel and recombinant human, 
acetylthiocholine iodide (ATCh), 5,5‟-dithiobis-2-nitrobenzoic acid (DTNB), and 
pralidoxime iodide were purchased from Sigma Co, Saint Louis, MO.  P6-DG desalting 
resin was obtained from Pierce.  ZipTip pipette tips were obtained from Millipore.  All 
the organophosphates and phosphonates were supplied by our collaborator Dr. Spilling at 
the University of Missouri, Saint Louis, MO. 
2.1.1  AChE assay: 
Both electric eel and human recombinant AChE were quantitated utilizing the 
extinction coefficients 101,550 and 119, 656 M-1cm-1 respectively, calculated from 
their amino acid sequences (Pace et al. 1995).  AChE (34 nM) was assayed utilizing 
Ellman‟s protocol (Ellman et al. 1961) using 160 µM acetylthiocholine (ATCh) as 
substrate and 300 μM 5,5‟-dithiobis-2-ntirobenzoic acid (DTNB) as coloring reagent 
in 100 mM sodium phosphate, pH 8.0, at 25°C in total volume of 1.6 ml in 3 ml 
cuvette.  A micro spinner was placed at the bottom of the cuvette for continuous 
mixing.  The thiocholine formed by enzyme hydrolysis reacts with DTNB and forms 
thionitrobenzoate anion, which gives absorption at 412 nm.  The assay was 
conducted using an HP8453 diode array spectrophotometer.  The absorbance at 412 
nm was monitored every 2 seconds for 30 seconds, and the slope (abs/sec) was 
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calculated using first 12–15 absorbance points to get the initial velocity of the 
reaction.  The abs/sec was then converted to μmol/min using the thionitrobenzoate 
extinction coefficient of 14,150 M-1cm-1. 
2.1.2  Test of IC50s of organophosphates (OPs) with AChE:  
The organophosphate and phosphonate inhibitors were solubilized in isopropanol 
(IP) and used in such a way so that the final concentration of the IP does not go beyond 
5% in the enzyme-inhibitor reaction medium.  The AChE from electric eel or human 
(34nM) was incubated with the inhibitor at increasing concentrations (in μM range) in 20 
mM Tris, 1% BSA, pH 7.5 at 25C for 30 mins.  The residual activity of the enzyme was 
assayed by Ellman‟s assay using acetylthiocholine (ATCh) (500 μM) as substrate and as 
a function of inhibitor concentration.  The substrate concentration maintained well above 
the Km of 46 μM for AChE (Radic et al. 1993).  The % residual activity was calculated 
and plotted against the inhibitor concentration.  The IC50 was determined as the 
concentration of inhibitor at 50% residual enzyme activity. 
2.1.3  Test of irreversibility of enzyme-inhibitor reaction: 
AChE from electric eel or human was incubated with inhibitor for 30 mins at 
25C in 20 mM Tris, pH-7.5 and passed through the P6DG gel filtration column (1 ml in 
volume and pre-equilibrated with 20mM Tris, pH 7.5).  The eluted enzyme was 
requantitated and assayed for residual activity.  P6DG is a desalting gel filtration column 
through which small molecules can be separated from a macromolecule; the protein 
elutes in the void volume leaving behind the small molecules like organophosphate or 
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phosphonates.  If the enzyme-inhibitor reaction is purely reversible, then the eluted 
enzyme shows reactivation because of efficient separation of enzyme from inhibitor.  For 
irreversible or covalent modification of the enzyme, the eluted enzyme remains 
inactivated.  The activity of the enzyme was expressed as μM/min.μM of enzyme so that 
the activity was always normalized by enzyme concentration. 
2.1.4  Time dependent irreversible experiment: 
To obtain the irreversible inhibition kinetic parameters like the inhibition rate 
constants (ki) and the inhibition equilibrium constant (KI), time dependent inhibition 
experiments were performed.  The loss of enzyme (here AChE) activity was measured as 
a function of pre-incubation time (min) and inhibitor concentrations (μM or nM) at 25C.  
The pre-incubation time was incremented by 5 mins up to 30 mins with few exceptions.  
The time-dependent loss of % residual activity of the enzyme is described below (Eqn 
1), assuming the enzyme-inhibitor reaction fits the irreversible two-step Model 1, having 
a reversible second order first step followed by a reversible first order second step.   
 
Model 1:  E = Enzyme, I = Inhibitor, EI = Enzyme-inhibitor complex, EI* = Enzyme-inhibitor 
dead-end complex, KI = inhibition equilibrium constant, k2 = forward rate constant for 
inactivation, and k-2 = reverse rate constant for inactivation (Callan OH 1996; Walker et al. 
2001). 
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At = A0 [(1 – k-2/kobs)* e-(kobs*t) + k-2/kobs]  Eqn. 1 
This equation represents a mono-exponential decay, where At equals the % residual 
activity at pre-incubation time (t), A0 represents the % residual activity at zero time i.e., 
the initial activity in the absence of inhibitor), and the observed rate of decay is kobs.   
The measured % residual activity as a function of pre-incubation time (min) and 
inhibitor concentrations (μM or nM) was globally fit with Eqn.1 using Scientist software 
to obtain the observed rate constant (kobs) and reverse rate constant for inactivation (k-2).  
The dependence of the observed rate constant (kobs) on inhibitor concentration is defined 
as: 
kobs = k2 * [I] / (KI +[I]) + k-2    Eqn. 2 
where kobs = observed rate constant, KI = inhibition equilibrium constant, k2 = forward 
rate constants for inactivation, and k-2 = reverse rate constant for inactivation.   
The observed rate constant (kobs) at different inhibitor concentrations ([I]) was 
plotted against inhibitor concentration [I] with estimation of k-2 from the global fit and fit 
using Kaliedagraph software to Eqn. 2 to obtain the estimated value of inhibition 
equilibrium constant (KI) and forward rate constant for inactivation (k2).   
Model 1 was intentionally designed to represent the global two-step reversible 
model.  Most of the irreversible inhibitors showed an extremely low k-2 value and were 
also analyzed using Model 2.  We also calculated pseudo-first order rate constant (ki) for 
each inhibitor by dividing KI from kinact. 
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Model 2:  E = Enzyme, I = Inhibitor, EI = Enzyme-inhibitor complex, EI* = Enzyme-inhibitor 
dead-end complex, KI = inhibition equilibrium constant, kinact = rate constant inhibition catalysis. 
2.1.5  Oxime reactivation reaction:  
The oxime reactivation experiments were conducted using pralidoxime iodide 
(shown in Fig. 2.1) as the oxime source.  First, the AChE from electric eel or human (34 
nM) was incubated with OP for 30 mins at 25C in 20 mM Tris, pH-7.5, then 
pralidoxime (final concentration 35 mM) was added to the reaction mixture and the 
residual activity of the enzyme was assayed at different incubation times (up to 2 hrs). 
2.1.6  MALDI-TOF analysis of proteolytic fragment of AChE: 
For the trypsinization of AChE – inhibitor complex, 10 µg of the enzyme was 
first incubated with inhibitor (1 mM) at 25°C for 30 mins in 20 mM Tris, pH 7.5 and 
centrifuged through a Microcon YM-3 (Millipore) (to get rid of excess inhibitor so that it 
does not affect the activity of trypsin) and denatured by incubating the retentant with 
0.1% SDS at 90°C for 45 mins.  The denatured enzyme was then incubated with 2 μg of 
trypsin at 37 °C for 2 h in 50 mM sodium phosphate, at pH 8.0 and 20% acetonitrile 
(CH3CN) (Wong et al. 2000; Kropp and Richardson 2007).  After incubation, the 
trypsinized AChE samples were lyophilized (if necessary) or analyzed.  The control 
 
 
53 
 
 
 
 
 
Fig. 2.1:  Reaction of AChE-organophosphate complex with oxime. 
Adapted from (Wong et al. 2000). 
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 sample (enzyme without the inhibitor) was also denatured and trypsinized by the above 
process. 
Lyophilized samples (both inhibitor treated and untreated) were suspended in 20 μl 
of 20% CH3CN solution containing 0.1%TFA, and incubated at room temperature for 10 
mins.  ZipTip (Millipore) C4 tips were activated in 70% CH3CN/0.1% TFA for 10 mins 
and washed 4 times with 20 μl of 20% CH3CN/0.1% TFA.  The 20 μl of trypsinized 
AChE was adsorbed to the tips by 15 cycles of 10 μl of aspirate and dispense steps.  Step 
gradient elution was performed by 3 cycle of 10 μl of aspirate and dispense steps at 
different CH3CN concentrations (e.g., 20, 25, 30, 35, 40, 60, and 80%) (15 μl each) 
containing 0.1% TFA.  5 μl of each elution fraction was mixed with 5 μl of of trans – 
3,5-dimethoxy-4-hydroxycinnamic acid (Sigma; 10mg/ml saturated solution in 40% 
CH3CN and 0.1%TFA) and spotted on MALDI-TOF/ MS target.  The spot was dried and 
placed inside the MALDI-TOF/MS probe for data collection.  Otherwise the Zip Tipped 
samples were lyophilized and submitted to the Mass-spectrometric facility of Danforth 
Plant Science Centre, Saint Louis, MO for MALDI-TOF analysis with Applied 
Biosystems Voyager-DE STR MALDI instrument. 
2.2  Inhibition studies of recombinant rat hormone-sensitive lipase (HSL): 
2.2.1  Cell culture: 
The Spodoptera frugiperda (Sf9) cells were grown in TNM-FH medium 
supplemented with 10% heat inactivated FBS, 100 units/ml penicillin G, and 100 µg/ml 
streptomycin at 27°C.  The cells were maintained in T-150 flasks (Fisher Scientific) and 
subcultured in 1:3 ratio whenever it reached 90% confluency. 
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2.2.2  Hormone-sensitive lipase preparation and purification: 
The rat hormone-sensitive lipase gene was obtained from Dr. F.B Kraemer‟s lab 
at Stanford.  The gene was cloned into a pcDNA3 vector using HindIII and XbaI sites.  
The HSL gene was subcloned in the pAcHLT-A baculovirus transfer vector (BD 
Biosciences), having N-terminal 6X-His Tag gene at a SmaI blunt cloning site.  The 
pAcHLT-A-HSL construct was transformed into TOP10F` E. Coli competent cells for 
large scale DNA production. 
Recombinant baculovirus containing the HSL gene was made us the HSL gene 
from the pAcHLT-HSL plasmid and the linearized Baculogold DNA (BD Biosciences; 
Cat. No. 21100D).  The transfection into Sf9 insect cells was accomplished by utilizing 
the CaII-phosphate precipitation method using a BaculoGold Transfection Kit (BD 
Biosciences; Cat. No. 560129).  The successful formation of recombinant baculovirus 
containing the HSL gene was confirmed by Western Blot analysis using a anti –rabbit 
HSL polyclonal antibody as the primary antibody (Cayman Chemicals Ltd.), and anti-
rabbit horseradish peroxidase (Promega) as the secondary antibody on the virus-infected 
cell lysate (Fig. 2.2) (Kraemer and Shen 2002; Kropp and Richardson 2007).   
Next, the recombinant virus was further proliferated to get a high titer virus 
solution.  From an end point dilution assay (BDBiosciences Baculovirus expression 
manual), the virus titer was estimated as 1 e7 pfu/ml.  For semi-large scale protein 
production, 7 e7 Sf9 cells were grown in T-150 (Fisher) flasks in TNM-FH medium 
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Fig. 2.2:  Western Blot analysis of recombinant HSL gene containing baculovirus 
infected Sf9 cell lysate.  Sf9 cells were infected with recombinant viral containing HSL 
gene.  After 3 days of incubation, the cells were lysed by using 1% digitonin (w/v) in 50 
mM Phos, pH 7.5.  SDS PAGE was performed on a denatured Sf9 cell lysate sample 
with a THP-1 cell lysate sample as a positive control.  The Western Blot was performed 
by using anti –rabbit HSL antibody as the primary antibody (Cayman Chemicals Ltd.) 
and anti-rabbit Horseradish Peroxidase (Promega) as secondary antibody.  Lane 1 is the 
Western blot of THP-1 lysate having all the three HSL isoforms (123 KD, 84 KD, and 56 
KD).  Lane 2 is the same for HSL gene cloned baculovirus infected Sf9 cell lysate.  In 
lane 2 Sf9 expressed recombinant HSL can be seen at 84 KD. 
123 kD 
56 kD 
84 kD 
THP-1 
Cell 
Infected 
Sf9 Cell 
HSL 
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 containing 10% FBS, 100 units/mL penicillin G, and 100 µg/mL streptomycin in 27°C 
incubator (without CO2) and infected with the recombinant virus at 5 m.o.i (multiplicity 
of infection; virus-to-cell ratio) (Ben Ali et al. 2004).  3 days after infection, the cells 
were harvested by centrifugation at 5,500 g for 7 mins and the cell pellet was collected 
and preserved at -80°C freezer for further analysis.  As HSL is not a secreted enzyme, the 
supernatant was discarded.   
For protein production, the cell pellet was resuspended in a 3 pellet equivalent 
volume of homogenization buffer containing 50 mM phosphate, pH 7.5, 25 mM sucrose, 
1 mM β-mercaptoethanol, 10% glycerol, and protease inhibitor cocktail (antipain, 
pepstatin, and leupeptin at final concentrations of 2, 1, and 2 µg/mL, respectively, Sigma; 
Cat. No. P8849) (Ben Ali et al. 2004).  The cell homogenate was sonicated (2 mins at 2 
setting followed by 2 mins at 4 setting with 30 sec interval in ice between each treatment) 
using Branson Sonifier 250 sonicator and centrifuged at 15,000 rpm for 15 mins at 4°C. 
As the expressed protein contained N-terminal 6X-His Tag, the resulting 
supernatant was collected and incubated with Ni-NTA beads (pre-equilibrated with    
50 mM Phos, pH 7.5, 20% glycerol, 0.3 NaCl, 1 mM β-mercaptoethanol, and protease 
inhibitor cocktail (buffer A)) for 45 mins at 4°C.  Next, the recombinant HSL-bound Ni-
NTA beads were washed with 4 bead volumes of buffer A containing 5 mM imidazole to 
prevent non-specific binding.  The protein was then eluted via imidazole concentration 
step gradient from 50 mM to 250 mM imidazole in buffer A (elution volume 300 μl)  
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(Fig. 2.3).  The fractions were evaluated by SDS-Page and the most pure elution 
fractions were pooled and dialyzed using Slide-A-lyzers (Pierce) against buffer A 
containing no imidazole.  The purified HSL was quantitated by UV spectrophotometry 
(Hewlett Packard 8453) using an extinction coefficient of 52,090 M-1 cm-1, calculated 
from its amino acid sequence  (Pace et al. 1995).   
2.2.3:  HSL assay: 
The assessment of HSL activity was done in two ways; a) by esterase assay, and 
b) by lipase assay.  Both assays were done to determine HSL activity, and they are 
described below. 
a)  Lipase Assay: 
The lipase assay of HSL was conducted by using 9, 10 - 3H labeled triolein 
(Perkin Elmer).  Triolein is a trioleylgycerol which is hydrolyzed by HSL to form free 
oleic acid.  The basis of the assay is to monitor the release of radio-labeled free oleic with 
time to obtain the rate of reaction.  The triolein was introduced to the enzyme through 
liposomes.  The liposome containing substrate was formed by mixing 
phosphatidylcholine, phophatidylinositol, and unlabelled triolein in a 1:3:1 ratio 
(Belfrage and Vaughan 1969).  500 μM of 20 ml triolein solution was prepared by adding 
20 μg of phosphatidylcholine, 75 μg of phophatidylinositol, 8855 µg of unlabeled triolein 
and 191cpm/fmol of 3H labeled triolein in chloroform.  The chloroform was evaporated 
by using rotavap in an N2 environment and adding 20 ml of buffer containing 25 mM 
Tris pH 7.4, 150 mM NaCl, 0.2 mM EDTA, and 1mM β-ME.  As liposome formation is 
energetically unfavorable, the mixture was sonicated (2 mins at 2 settings 
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Fig. 2.3:  SDS-PAGE gel from recombinant rat HSL purification using Ni-NTA 
beads.  Step gradient of imidazole from 50 mM to 250 mM was used to elute the Ni-
NTA bound 6X-His tag HSL.  The SDS PAGE was performed on denatured elution 
fractions and the above image was acquired.  SDS gel image shows the amount of 
protein present in each fractions and their purity.  Lane 1 is protein molecular weight 
marker (NEB), lane 2, 3, 4, and 5 are crude extract, flow through of loading, washing 1, 
and washing 2 respectively. Lane 6, 7, 8, 9, 10, and 11 are elution at 50, 100, 150, 200 
and 250 mM imidazole solution.  The purified HSL can easily be seen at 84 kD. 
1        2      3     4       5      6      7       8     9      10   11 
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83 
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 and 2 mins at 4 setting) by a Branson sonifier (Belfrage and Vaughan 1969).  The 
sonified solution was then cooled to room temperature, and 0.1 % BSA was added.  The 
resulting emulsion was used as a stock solution of substrate. 
The reaction of HSL with liposome-containing substrate was conducted on a 600 
μl scale.  480 μl of the substrate was incubated with 120 μl of 100 nM HSL (depending 
on the concentration required) at 37°C for 40 mins.  The reaction was quenched by 
adding 600 μl of methanol:chloroform:heptane (1.41:1.25:1) solvent mixture and 300 μl 
of 50 mM potassium carbonate - potassium borate - potassium hydroxide buffer at pH 
10.  The resulting mixture was vigorously vortexed for 7 mins and centrifuged at 13,000 
rpm for 10 mins.  The extraction was repeated.  The upper aqueous layer containing 
radiolabeled free fatty acid was collected, and the radioactivity was determined via liquid 
scintillation.  The reaction was monitored for 30 mins, and every 5 mins 100 μl of the 
aliquot was withdrawn and quenched by the above mentioned solutions, and the 
radioactivity was evaluated.  The rate was calculated from the slope of cpm vs. time, and 
the rates were expressed in terms of µmol/min per mg of enzyme. 
b)  Esterase Assay: 
The esterase activity of HSL was determined by using water soluble p-nitrophenyl 
butyrate (p-NPB) as a substrate.  For the assay of HSL (100 nM), p-NPB in 100% 
acetonitrile was added to 100 mM Phos pH 7.2, 150 mM NaCl, and 0.5% Triton X-100 
at 25°C (Shirai et al. 1982).  HSL hydrolysis of p-NPB obtained yellow color p-
nitrophenol, which absorbs at 400 nm.  The increase in absorbance at 400 nm was 
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recorded every 30 secs for 5 mins.  The reaction rate was calculated in abs/sec using first 
6 to 8 absorbance points and converting to µmol/sec by utilizing the extinction co-
efficient of p-nitro phenol as 14,200 M−1cm−1 at 400 nm. 
2.2.4  Test of IC50s of organophosphates (OPs) with HSL: 
The HSL activity was tested in the presence of two types of organophosphates; 
one having long carbon chain fatty acid-like substituents and another without (e.g., DIFP, 
compound 2a, 2b). 
The water insoluble carbon chain substituted inhibitors were introduced to the 
enzyme through liposomes.  First, a stock solution of phosphatidylcholine (PC) and 
phophatidylinositol (PI) mixture, having a concentration of 1.4 μM and 4.2 μM 
(respectively) was prepared in chloroform.  Varying volumes of 148 mM inhibitor 
isopropanol solution were mixed with 9.33 μl of PC/PI solution to make 1 ml liposome-
embedded inhibitor solution of different concentrations.  Solvent was evaporated, and 1 
ml of buffer containing 25 mM Tris pH–7.4, 150 mM NaCl was added to it.  Next the 
mixture was sonicated for 2 mins at 2 setting and 2 mins at 4 setting.  Thus, different 
concentrations of inhibitor solutions (e.g., 100, 200, 400, 800, and 1600 μM) were made 
keeping the PC/PI composition constant.  For IC50 determination, 100 nM of HSL was 
incubated with liposome-embedded inhibitor solution at varying concentration for 30 
mins at 37°C.  The residual activity of the enzyme after the reaction was determined by 
assaying the enzyme-inhibitor mixture using either lipase or esterase assay method 
described above.  The lipase and esterase assays were conducted using 50 μM of triolein 
and 5 mM p-NPB, which were 15 and 10 fold higher than their respective Kms, 3.4 μM 
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and 0.59 mM (Osterlund et al. 1996; Shen et al. 1998).  The IC50 was determined as the 
concentration of inhibitor at 50 % residual activity of the enzyme.   
2.3  Hormone-sensitive lipase translocation to lipid droplets in 3T3-L1 adipocyte 
cells: 
2.3.1  Cell culture: 
The 3T3-L1 cells (ATCC) were grown in Dubelcco‟s Modified Eagle Medium 
(DMEM) supplemented with 10% FBS (Hyclone), 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 µg/ml streptomycin at 37ºC in 5% CO2.  The cells were sub-cultured 
every three days at the density of 7000 cells/cm2.  The cells were fed with the new 
medium every couple of days and never allowed to be more than 70% confluent. 
2.3.2  Differentiation of 3T3-L1 cells: 
The pre-adipocyte 3T3-L1 cells were obtained from ATCC.  For the HSL 
translocation experiment, the cells are required to be differentiated and to have mature 
lipid droplets and a well-defined cytoplasm and nucleus.   
For differentiation, the cells were grown to confluency in DMEM medium 
containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37ºC in 5% 
CO2.  At two days of post-confluency, the cells were stimulated with medium containing 
10% FBS, 175 nM insulin (Sigma), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX; 
Sigma), 0.25 µM dexamethasone (Sigma), 2 mM L-glutamine, 100 U/ml penicillin, and 
100 µg/ml streptomycin (Wolins et al. 2006).  After two days of incubation at 37ºC in 
5% CO2, the medium was changed to insulin medium containing 200 nM insulin, 10% 
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FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin.  It generally 
took 7-8 days post confluency to achieve full differentiation of 3T3-L1.  The 
differentiated cells were maintained in normal DMEM growth medium. 
2.3.3  Expression of YFP-fused HSL in 3T3-L1: 
The rat HSL gene was subcloned in to the pTag-YFP (Evrogen) vector at the C-
Terminal of YFP at the HindIII/XbaI site.  The pTagYFP-HSL construct was then 
transfected into 3T3-L1 cell using Lipofectamine 2000 (Invitrogen; Cat. No. 11668-027) 
transfection reagent.  0.8 μg of pTagYFP-HSL and 2 μl of Lipofectamine 2000 were 
mixed together and incubated for 5 mins at 25°C, and the mixture was added to the wells 
of 24 well plates having 2 x 105 3T3-L1 cells.  After 8 hrs of incubation at 37°C in 5% 
CO2, the transfection medium was replaced with growth medium and incubated for 
another 24 hrs at the same temperature.  Two days post transfection the cells were 
screened for transfected cells in the presence of antibiotic, geneticin (600 μg/ml) 
(Bayers‟ Chemical).  Next, the expression of YFP-HSL was verified by performing 
Western Blot or by direct imaging of YFP expression (Fig. 2.4) through Carl Zeiss 700 
Laser Scanning Confocal Microscope at Centre for Nanoscience, UMSL. 
2.3.4  Lipid droplet staining by BODIPY-C12 in 3T3-L1 cells: 
The lipid droplets in differentiated 3T3-L1 cells were stained by BODIPY-C12 
dye.  First, 500 µl of 8 % BSA (final concentration 2 %) was sonicated (2 mins at 2 
settings) with 10 µl of oleic acid (final concentration 1.8 mM) in phosphate buffer saline 
(PBS), then the resulting emulsion was mixed with BODIPY-C12 (20 µg/ml), 2 µl of 167  
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Fig. 2.4:  A confocal image of YFP-HSL protein in pre-adipocyte 3T3-L1 cell.  3T3-
L1 cells were transfected by pTagYFP-HSL DNA and screened for positively transfected 
cells using geneticin (600 μg/ml).  After the screening process, the transfected cells were 
grown for additional 2 days in growth medium.  Next the cells were subcultured in a 
MatTek dish and a confocal image was collected using a Carl Zeiss 700 Laser Scanning 
Confocal Microscope.  The excitation wavelength was 508 nm and the emission was 
detected at 520 – 610 nm. 
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µM of insulin and 100 µl of 0.5 M glucose.  The total volume of the mixture was 
adjusted to 2 ml.  The whole solution was laid on the differentiated 3T3-L1 cell bed in 
MatTek (MatTek corp.) dish and incubated for 2.5 hours.  The cell density in the MatTek 
dish was maintained such that the cells could get plenty of space to spread their cell 
structure.  After the incubation, the cells were gently (no vigorous agitation) washed 
three times with PBS and confocal images were taken.  Fig. 2.5 shows the BODIPY 
stained lipid in the differentiated 3T3-L1 cells.  
2.4  1-anilinonaphthalene-8-sulphonate (1, 8-ANS) binding to rat HSL: 
1-anilinonaphthalene-8-sulphonate (1, 8-ANS) (Molecular Probes) is a small 
organic molecule that is non-fluorescent in water but fluoresces when comes in contact 
with any organic solvent or hydrophobic surface of protein (Parker et al. 1967; Tanaka et 
al. 2006).  The excitation and emission wavelength of protein-bound 1, 8-ANS is 
reported as 375 nm and 480 nm, respectively (Parker et al. 1967) (Fig. 2.6).  A Fluorolog 
3 spectrofluorimeter (Horiba Jobin Yvon) was used to perform the experiments.  A nitric 
acid cleaned quartz cuvette (NSG scientific) was used and 25ºC temperature was 
maintained during the experiments using an external water bath. 
Normally, 100 µM of 1, 8-ANS was reacted with 1 µM of HSL at 25ºC in 
membrane filtered 50 mM Tris, pH 7.5 solution in a total volume of 700 µl and the 
fluorescent emission spectrum was taken at 487 nm by exciting the ANS at 380 nm.  The 
rat HSL was dephosphorylated by incubating it with 2 units of PP2ase (Promega) in the 
same buffer condition at 25ºC for 30 mins.  For consecutive phosphorylation of the 
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Fig. 2.5:  BODIPY-C12 stained differentiated 3T3-L1 cells.  The normal 3T3-L1 cells 
were differentiated (protocol mentioned in the text) and then the cells were stained with 
BODIPY-C12 (20 µg/ml) for 1 hr at 37ºC (protocol in the above text).  The cells were 
washed with PBS three times and confocal images were taken.  The picture at left was 
taken using Zeiss confocal imaging microscope (CNS, UMSL) in track 1 with the 
following parameter set:  Lense: 63X, laser power master gain = 350, pin hole = 1AU, 
excitation at 500 nm and emission at 510 nm in Smart setup.  For normal cell picture at 
right in track 2 the parameters sets were following:  lense: 63X, laser power master gain 
= 304, pin hole = 1AU, transmitted light (T-PMT) in Smart setup. 
T-PMT BODIPY 
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Fig. 2.6:  1, 8-ANS excitation and emission spectra.  The blue curve represents the 
excitation spectra of 1, 8-ANS, whereas the red curve represents the emission spectra of 
the same when it is bound to any hydrophobic entity like protein hydrophobic surface or 
any organic solvent.  Adapted from (Parker et al. 1967). 
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 enzyme, first it was treated with 10 nM of okadaic acid (a PP2ase inhibitor) for 15 mins 
and then incubating it with 200 µM ATP, 10 mM MgCl2, and 10 units of c-AMP 
dependent PKA at 25ºC for 30 mins in same reaction buffer stated above.   
2.5  Dynamic light scattering (DLS) experiment of HSL inhibitors in aqueous 
solution: 
According to the classical theory of light scattering, when light passes on the molecule, 
the electric field of the light induces an oscillating polarization of electrons in the 
molecule. The molecules then become a secondary source of light and scatter the 
impinged light. The frequency shifts, the angular distribution, the polarization, and the 
intensity of the scatter light are determined by the size, shape and molecular interactions 
in the scattering material (Brookhaven Instruments; Berne and Pecora 1975).   
All DLS experiments were conducted using a Particle sizer (Brookhaven 
Instruments) located in Dr. George Gokel‟s lab in Center for Nanosciences (CNS) at 
UMSL.  A solution of compound 24 or the liposome containing 24 (Chapter IV) was 
prepared in 50 mM Tris, pH–7.5 at 25ºC.  The reaction volume was maintained as 1.2 ml 
in disposable cuvettes.  After the sample was exposed to the laser source in the machine, 
it automatically generated a plot of autocorrelation function vs time (μs) plot; the actual 
data was generated from the secondary plot of intensity vs diameter (Fig. 5.3).  The 
autocorrelation function (Gτ) relates to the diffusion co-efficient (D) like Eqn 3 (Berne 
and Pecora 1975),  
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                                     Eqn 3 
where G(τ) = autocorrelation function, τ = time in μsecs, D = diffusion co-efficient, K = 
measurement vector, η = refractive index of the solution (1.33 for water), λ = wave 
length of the laser (generally 632.4 nm), θ = angle of scattering. 
Again, the diffusion co-efficient (D) can be related to the diameter of the particle 
or molecule by Eqn 4,  
                                             Eqn 4 
where d = diameter of the particle or molecule (m), T = absolute temp, η = diluent 
viscosity (water = 8.94*10-4 kg/(ms) and kB = Boltzmann constant (1.3807*10
-23 J/K). 
2.6  Structure aided multiple sequence alignment (SSAMSA) of HSL and CRL 
using SwissPDB Viewer: 
SSAMSA has been done using SwissPDB Viewer‟s (Guex and Peitsch 1997) 
special tool named „magic fit‟.  In this process the amino acid sequence of CRL (used as 
template) is fed to the program and the C-terminal amino acid sequence of rat HSL (1-
367) is then provided.  When „magic fit‟ is turned on the program used the SSAMSA and 
other energy minimization method to come up with a suitable secondary structure of the 
HSL according to the template provided (Fig 5.2). 
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CHAPTER III 
INHIBITION STUDIES OF ACETYLCHOLINESTERASE IN 
PRESENCE OF THE BICYCLIC PHOSPHONATE ANALOG OF 
CYCLOPHOSTIN 
3.1  Acetylcholinesterase (AChE) inhibition and structure-activity relationship of 
laboratory synthesized organophosphates (OPs): 
As discussed in Chapter I, acetylcholinesterase (AChE) belongs to the serine 
hydrolase (SH) superfamily of enzymes.  This family of enzymes contains serine as one 
of the catalytic amino acids in their active sites.  Including serine, the active site of the 
enzyme contains two other highly important amino acid residues, aspartic acid and 
histidine, which are involved in hydrolyzing the natural substrate acetylcholine (ACh) 
(Rosenberry 1975).  ACh, the natural substrate of AChE, is a neurotransmitter which 
helps transporting information from one neuron to another (Maelicke and Albuquerque 
2000).  It has been proposed that AChE can be a drug target for neuronal disorder 
diseases (Millard and Broomfield 1995; Cutler and Sramek 2001).  In AD patients, the 
accelerated hydrolysis of ACh enhances the risk of memory loss, which could be 
prevented if the hydrolyzing enzyme AChE is inhibited.  Most of the inhibitors available 
for AChE are laboratory synthesized (Lahiri et al. 2004; Eckert et al. 2006; Belluti et al. 
2009).  There are very few natural product inhibitors of AChE known to scientists; they 
are physostigmine, huperzine-A, and fasciculin (Fig. 1.8 in Chapter I).  
Organophosphates (OP) are one of the most extensively used inhibitors of AChE (Kam et 
al. 1993; Winkler et al. 1996; Glynn 1999).  OPs like soman, tabun, VX, and paraoxon 
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are all laboratory synthesized compounds (Fig. 1.9 in Chapter I), which are utilized to 
study AChE inhibition (Worek et al. 2004).   
3.1.1  Test of IC50s for laboratory synthesized organophosphates (OP) against 
human and electric eel AChE: 
Cyclophostin is a bicyclic phosphate, which is reported to be one of the most 
potent organophosphate based natural product inhibitors of AChE (Table 1.2 in Chapter 
I and Table 3.1) (Kurokawa et al. 1993).  As listed in Table 3.1 the IC50 of cyclophostin 
is 0.8 nM against insect AChE.  Our collaborator synthesized the bicyclic phosphonate 
analog of cyclophostin along with a variety of other cyclic and acyclic phosphonates (see 
Table 3.1).  The potencies of all laboratory synthesized compounds were tested against 
human and electric eel AChE using Elman‟s assay (Ellman et al. 1961).  The IC50s of all 
the laboratory synthesized compounds are listed in Table 3.1 (Bandyopadhyay et al. 
2008; Dutta et al. 2010). 
As reported in (Bandyopadhyay et al. 2008), one diastereoisomer of bicyclic 
phosphonate analog of cyclophostin was more potent (2a) than the other one (2b), when 
tested against both human and electric eel AChE.  The diastereospecificity of 2a and 2b 
against human and electric eel AChE is shown in Fig. 3.1A and B.  The IC50 for 2a 
against house fly AChE is 0.8 µM, almost 10 times more potent than 2a against human 
AChE.  Though the species specific potencies of compound 2a and 2b were quite 
attractive in terms of designing more potent inhibitors, the highest potency of 2a against 
house fly AChE (IC50 0.8 µM ) was still 1000 times less than the potency of natural 
product (1) against insect AChE (IC50 8 e-4 µM) (Kurokawa et al. 1993).   
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Table 3.1:  IC50s of organophosphates against AChE from different sources. 
Compound Structure  IC50, μM 
Human Eel Fly  
 
1a 
  
N.D 
  
8e-4  
 
 
2ab, c 
  
3 
 
70 
 
N.D 
 
 
 
2bb, c 
 
 
3ab, c 
 
 
 
 
 
 
30 
 
 
≈ 35 
 
 
400 
 
 
150 
 
 
N.D 
 
 
N.D 
 
 
3bb, c 
 
 
 
 
 
≈ 6 
 
100 
 
N.D 
 
9c  7 300 N.D  
 
 
10c 
  
 
600 
 
 
N.D 
 
 
N.D 
 
 
 
15c 
  
 
5 
 
 
N.D 
 
 
N.D 
 
 
21bc 
  
 
70 
 
 
N.D 
 
 
N.D 
 
 
21ac 
  
>1000 
 
N.D 
 
N.D 
 
 
 
DIFPc 
 
  
 
   0.12 
 
 
  N.D 
 
 
 N.D 
 
N. D = Not Determined. 
a(Kurokawa et al. 1993); b(Bandyopadhyay et al. 2008); c(Dutta et al. 2010) 
8 7 
6 
4 5 3 
2 
1 
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Fig. 3.1:  Diastereospecificity of 2a and 2b against human and electric eel AChE. 
A:  34 nM human AChE was incubated with 1, 2.5, 5, 10, 20, 40, and 80 µM of 2a and 
2b for 30 mins at 25C.  The % residual activity of the enzyme was obtained using 
Elman‟s assay and plotted against inhibitor concentration.  The data points are connected 
to guide the eyes.  B:  34 nM electric eel AChE was incubated with 20, 40, 80, 160, and 
320 µM of 2a and 2b for 30 mins at 25C and is the same as in A.  Adapted from (Dutta 
et al. 2010). 
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The relative configuration of the most potent inhibitor 2a is opposite compared to the 
natural product (1); in 2a the methoxy group attached to the central P-atom and the H-
atom at junction C4 are located on opposite faces of the molecule, whereas for 1 it is at 
the same face.  We have to keep in mind that the synthesis of the bicyclic phosphonate 
analogs were done using achiral phosphono carbonate (Bandyopadhyay et al. 2008), and 
as a result, the individual compounds 2a and 2b are actually a mixture of two isomers.  
Even though the relative configuration of 1 is similar to 2b, it is possible that one of the 
isomers constituting compound 2b is particularly unsuitable for the AChE active site and 
contribute the less potency.  In addition, we should not forget about the contribution of 
O5 in 1 for enhancing its electrophilicity of P6 compared to the presence of C5 in 2a (see 
the numbering in 1).   
Interestingly, the monocyclic compounds 3a, 3b, and 9 that lack the lactone ring 
showed similar IC50s (35, 6, and 7 µM for human AChE and 150, 100, and 300 µM for 
eel AChE) to the bicyclic analogs (Dutta et al. 2010).  It seemed from the IC50 that the 
lactone ring did not have much contribution towards the potency of the bicyclic 
compound, but binding constant data (discussed in later sections) indicates that there is 
considerable contribution from the lactone ring in this regard.  Interestingly, reduction of 
the ester in 9 to 10 (an alcohol) decreased the potency up to 100 fold, a phenomenon 
which indicates the electron withdrawing contribution of ester in augmenting the leaving 
group characteristics of the enol from the P–center (Bandyopadhyay et al. 2008).  It is 
also possible that carbonyl carbon of the ester is involved in some hydrogen bond-
accepting contacts with the AChE active site residues (see later sections).  Moreover, 
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compound 17b, the E isomer of the compound pair having intact lactone ring, showed 
much better activity (70 μM) than the Z isomer, compound 17a.  This indicates that not 
only a cyclic phosphonate-like structure is necessary, but there is also a requirement of 
structural alignment between P-center and lactone ring for better inhibitory potency 
against AChE.   
Though the results from Table 3.1 illustrate the structure activity relationship of 
cyclic and acyclic phosphonates against AChE, the optimum potency of the laboratory 
synthesized compounds could not exceed the potency of conventional AChE inhibitor, 
DIFP.  This phenomenon has both advantages and disadvantages in terms of AChE 
inhibitor designing in future (discussed later). 
3.1.2  Mechanism of inhibition of human and electric eel AChE by cyclic 
phosphonates: 
Kurokawa T et al. (1993) reported the inhibitory potency of cyclophostin against 
AChE in terms of IC50s.  They did not perform any mechanistic studies to establish the 
mode of action of the inhibitor against AChE.  To establish the mechanism of inhibition, 
rigorous and detail analysis of inhibition was conducted.  Generally, the OPs inhibit the 
AChE in an irreversible manner (Fig. 1.10 in Chapter I).  I tested the most potent 
inhibitor in our hand, compound 2a, for its irreversible nature of inhibition. 
The AChE from human and electric eel were incubated with compound 2a for 30 
mins at 25ºC and passed through a P6DG column; the eluted enzymes in the void volume 
were quantitated and tested for activity (see experimental detail in Chapter II).  P6DG 
retains the small molecules and lets the macromolecule elute at the void volume.  If the 
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inhibitor is reversible, which means the interaction of inhibitor with the active site of the 
enzyme is non-covalent, then the eluted enzyme shows reactivation due to the small 
molecule partitioning in the desalting column.  An irreversible inhibitor, which 
covalently modifies the enzyme active site and/or other sites, remains attached with the 
eluted enzyme and thus the enzyme is not re-activated even upon desaltation.  Fig. 3.2a 
and 3.2b show the irreversible nature of compound 2a against human and electric eel 
AChE on the time scale of the experiment.   
To determine the exact mechanism of inhibition, % residual activity of the 
enzyme was recorded as a function of inhibitor concentration and incubation time for all 
potent compounds (IC50 in low μM range) against human AChE (Fig. 3.3, Fig. 3.4, and 
Fig. 3.5).   
To elucidate the mechanism of inhibition, Model 1 (explained in Chapter II) is 
utilized rather than the conventional Kitz and Wilson irreversible inhibition model (Kitz 
and Wilson 1962).  The Model 1 was more general and can explore the reversible 
inactivation step.  Observed rate constants (kobs) were determined by the global fit of the 
% residual activity vs pre-incubation time data using Scientist program.  The kobss were 
then plotted against the inhibitor concentrations to obtain the equilibrium inhibition 
constant (KI), forward rate constants for inactivation (k2), and reverse rate constants for 
inactivation (k-2).  The KI of 2b is almost 10 times the KI of 2a (considering the 
experimental error involved in the analysis) (Table 3.2), reflecting the IC50 data (Dutta et 
al. 2010).  Interestingly, the forward rate constants for inactivation (k2) for both 2a  
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Fig. 3.2:  Test of irreversibility of 2a-human/electric AChE reaction.  A:  34 nM 
human AChE was incubated with 20 µM of 2a for 30 mins at 25C in 20 mM Tris-Cl, 
pH-7.5 and passed through a P6DG desalting column.  The enzyme was collected at the 
void volume, re-quantitated and assayed for activity.  E represents the activity of enzyme 
incubated in buffer for 30 min and subjected to desalting. E + I represents the % residual 
activity of enzyme treated with inhibitor for 30 min but not desalted. For E + I the 
average activity for three trials was 0.2% of initial activity. E + I + desalt represents the 
activity of enzyme incubated with inhibitor for 30 min and purified by desalting gel.  B:  
The same analysis was done with 34 nM electric eel AChE in presence of 200 µM of 2a.  
All the designations in the plot are same as A.  For E + I the average activity for three 
trials was 1.0 % of initial activity.  Error bars were generated from three independent 
experiments.  Adapted from (Dutta et al. 2010) 
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Fig. 3.3:  Kinetics of inhibition of human AChE in presence of 2a and 2b.  The left 
column shows the % residual activity as of function of pre-incubation time.  Right 
column shows kobs (min
-1) as a function of inhibitor (µM).  The kobss in the right column 
were obtained from the % residual activity vs pre-incubation time plot at the left column 
using Model 1 (see Chapter II).  The data in the kobs (min
-1) vs inhibitor (µM) plot were 
fit with Eqn 2 (see Chapter II) to obtain KI, k2, and k-2.  Upper panel shows the kinetic 
study of 2a against human AChE; 2a = 0.5 (black circles), 1.0 (green squares), 2.0 (pink 
diamonds), 4.0 (brown triangles), 8.0 (half filled squares), and 16.0 µM (crossed violet 
squares).  The lower panel shows the kinetic study of 2b against human AChE; 2b = 5 
(black circles), 10 (pink squares), 20 (grey diamonds), 40 (brown triangle) 80 (half filled 
blue squares), and 160 µM (crossed violet squares).  Adapted from (Dutta et al. 2010). 
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Fig. 3.4:  Kinetics of inhibition of human AChE in presence of 9 and 15.  The left 
column shows the % residual activity as a function of pre-incubation time.  Right column 
shows the kobs (min
-1) as a function of inhibitor (µM).  The kobss in the right column were 
obtained from the % residual activity vs pre-incubation time plot at the left column using 
Model 1.  The data in kobs (min
-1) vs inhibitor (µM) plot at the right column were fit with 
Eqn 2 (see Chapter II) to obtain KI, k2, and k-2.  Upper panel shows the kinetic study of 
9 against human AChE; 9 = 5 (black circles), 10 (pink squares), 20 (brown diamonds), 
40 (grey triangles), and 80 µM (half filled blue squares).  The lower panel shows the 
kinetic study of 15 against human AChE; 15 = 5 (black circles), 10 (pink squares), 20 
(brown diamonds), 40 (orange open circle), and 80 µM (half filled blue squares).  
Adapted from (Dutta et al. 2010). 
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Fig. 3.5:  Kinetics of inhibition of human AChE in presence of DIFP.  The left panel 
shows the % residual activity as a function of pre-incubation time.  Right panel shows 
the kobs (min
-1) as a function of inhibitor (µM).  The kobss in right column were obtained 
from the % residual activity vs pre-incubation time plot on the left column using Model 
1.  The data in kobs (min
-1) vs inhibitor (µM) plot at the right were fit with Eqn 2 (see 
Chapter II) to obtain KI, k2, and k-2.  9 = 2 (black circles), 4 (pink diamonds), 8 (grey 
inverted triangle) and 16 µM (half filled green squares).  Adapted from (Dutta et al. 
2010). 
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Table 3.2:  Kinetic parameters of inhibition of human AChE by laboratory 
synthesized OPs. 
Compound Structure Kinetic parameters 
KI (µM) k2 (min
-1) k-2 (min
-1) 
 
2a 
  
24 ± 6.0 
 
0.3  ± 0.06 
 
0.02 
 
 
2b 
  
 
140 ± 58 
 
 
0.4 ± 0.1 
 
 
0.01 
 
 
9 
  
 
76  ± 20 
 
 
0.2  ± 0.03 
 
 
0.01 
 
 
15 
  
 
312  ± 134 
 
 
4.2 ± 1.5 
  
 
0.13 
 
 
DIFP 
 
 
 
 
 
 
 
6.0±1.0 
 
 
1.0±0.1 
  
0.13 
Adapted from (Dutta et al. 2010). 
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and 2b are similar, indicating the fact that the initial binding of the compounds to the 
active site of AChE was the determining factor for potency.  Ten fold reverse rate 
constants for inactivation (k-2) for both 2a and 2b compared to forward rate constant (k2) 
confirmed the irreversible nature of the mechanism.  The data indicate that distereomeric 
preference of 2a by AChE is due to some specific initial contacts between 2a and active 
site amino acid residues, which ultimately led to a successful inhibition.  Moreover, 
compound 2a showed 3-fold more affinity towards AChE than compound 9, a 
monocyclic seven membered ring phosphonate, indicating the necessity of bicyclic entity 
or the lactone ring towards inhibitory activity.  From a SAR point of view, if the ring 
strain is the sole reason for the reactivity of cyclic phosphonate, then reducing the ring 
size would give more potency against AChE.   
Interestingly, compound 15, a six membered monocyclic phosphonate, showed 
almost 10 times less affinity for AChE than compound 2a.  But the sole reactivity of 
compound 15 was reflected in its 14 times higher inactivation rate constant.  It seems 
from the analysis that the seven-membered ring structure was optimum for moderate 
activity of the cyclic phosphonate.  Though the six-membered ring phosphonate, 
compound 15, showed similar activity with 2a in terms of IC50, the less tight initial 
binding of 15 could affect its specificity towards AChE active site, and thus might 
become a poor candidate as a potent inhibitor.   
In terms of reactivity, DIFP shows 3 times higher affinity and 1 order of 
magnitude higher inactivation rate constant toward human AChE active site than 2a.  
DIFP being a very strong nerve agent and already rejected as a drug option for 
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Alzheimer‟s disease, the milder option of 2a may give an extra edge for successful drug 
discovery in the future.   
3.2  Active site serine modification of AChE by cyclic phosphonate: 
3.2.1  Oxime reactivation of OP-AChE complex: 
Oxime is an antidote for nerve agents like sarin, soman, and VX (Marrs et al. 
2006).  As shown in Fig. 2.1 in chapter II, oxime nucleophilically attacks the P –atom of 
OP-AChE complex and reactivates AChE by replacing the OP moiety from the active 
site.  But sometimes even oxime cannot reactivate the inactivated OP-AChE complex 
because of a post complex modification of OP-AChE (Fig. 3.6).  The common post 
complex modification is the aging reaction (Sultatos 1994).  In the aging process, the 
active site water attacks the central phosphonate P and eliminates the O-alkyl group,  
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Fig. 3.6:  Probable fate of human AChE-2a complex.  Route A:  2a covalently 
modifies the human AChE active site serine and forms a complex similar to the structure 
shown at the extreme left of the above picture.  Pralidoxime can reactivate the 2a 
inhibited human AChE by attacking the P-center.  Nucleophilic attack of the oxime O-
atom at the P-center of the complex may yield reactivated enzyme and OP-pralidoxime 
complex.   
Route B:  The AChE-2a adduct can also be attacked by an active site water molecule and 
may yield an inactivated enzyme having a less electrophilic P-centre.  The resulting 
complex may be hard to reactivate even after oxime treatment. 
Route A 
Route B 
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which makes the P-centre less electrophilic and less vulnerable to oxime reactivation.  If 
the OP-AChE complex undergoes aging, the oxime reactivation of inactivated AChE 
becomes difficult and it becomes almost impossible to reactivate the enzyme.  Sarin and 
VX are the best examples of OPs that undergo productive aging reactions (Millard et al. 
1999; Nachon et al. 2005). 
Fig. 3.7 shows that the reaction of 35 mM pralidoxime at two different incubation 
times (30 and 120 mins) with the 2a-AChE complex showed no more than 5% 
reactivation, considering pralidoxime‟s own effect of inhibition on AChE (Dutta et al. 
2010).  The reactivation of eel AChE was more significant (~13 % of actual enzyme 
activity) compared to human AChE; it is may be due to the lower activity of 2a toward 
eel AChE or a slight difference in the active site geometry and constituent amino acid 
residues.   
The above fact suggests to several possible mechanistic outcomes.  The small 
reactivation could be either due to the aging process showed in Fig. 3.6 or due to the 
modification of enzyme at sites other than the active site of the enzyme.  It has been 
previously reported that the structure of the oxime also influences the reactivation 
process (Musilek et al. 2008; Kassa et al. 2009).  Trp86, in the vicinity of the active site 
catalytic triad, participates in a π-cation interaction with an aromatic oxime and 
facilitates the nucleophilic attack of oxime O-atom on the P-centre of the OP-AChE 
complex (Sanson et al. 2009).  It is possible that after the covalent modification by 2a, 
the conformation of Trp86 changed, which in turn hinders the binding of the oxime to the 
Trp86 and results in poor reactivation of OP-AChE complex.  The reactivation rate  
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Fig. 3.7:  Pralidoxime reactivation of human AChE-2a complex.  A:  34 nM human 
AChE was incubated with 10 µM of 2a for 30 mins at 25°C in 20 mM Tris-Cl, pH-7.5.  
35 mM pralidoxime was introduced and % residual activity of enzyme was determined.  
E + P, enzyme and pralidoxime control. E + I, enzyme and inhibitor control.  E + I + P, 
enzyme and inhibitor and pralidoxime (see Chapter II for detail).  All rates are 
expressed relative to the enzyme control at the same time point in the experiment.  B:  
Same analysis was done using 34 nM electric eel AChE in presence of 150 µM of 2a and 
35 mM pralidoxime.  Adapted from (Dutta et al. 2010). 
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of 2a-AChE complex by pralidoxime is evaluated to be 0.04 min-1 which is very close to 
the value of 0.05 min-1, the reactivation rate found for DIFP-AChE complex by 
pralidoxime (Worek et al. 2004).  This indicates that the low reactivation is not unique 
for 2a-AChE complex; reactivation experiments using different oximes or mutational 
studies may be needed to yield some evidence to explain this.  Finally, it can be 
concluded from Fig. 3.7 data that pralidoxime has very little or no effect on reactivating 
the OP-AChE complex.  
3.2.2  Mass Spectrometric analysis of trypsinized inhibitor-AChE complex: 
To established covalent modification at the active site serine, human AChE-2a 
complex was subjected to proteolysis by trypsin, ZipTip purification and MALDI-TOF 
mass spectrometry (Dutta et al. 2010). 
The theoretical mass of the peptide fragment (L178-R219) containing the active 
site serine is 4269.8 Da.  The mass is calculated by feeding the human AChE amino acid 
sequence in to the MSDigest program (UCSF, bioinformatics tools) in trypsin mode of 
proteolysis.  A peptide with a mass of 4267.9 Da was obtained from the MALDI-TOF 
data of trypsinized human AChE (Fig. 3.8).  The mass shifted to 4500 Da when 
trypsinized human AChE-2a complex was subjected to MALDI-TOF (Fig. 3.8).  2a has 
a molecular weight of 232 Da and existence of 4500 Da fragment in human AChE-2a 
MALDI-TOF data indicates covalent modification at the active site serine yielding a 
(4267.9+232) Da fragment. 
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Fig. 3.8:  MALDI-TOF evidence of covalent modification of human AChE active 
site serine.  A:  The figure shows the expected peak at 4268 Da for the (L178-R219) 
peptide fragment containing the active site serine.  B:  Human AChE was incubated with 
2a for 30 mins at 25°C and analyzed similarly.  The figure shows the peak at 4500 Da, 
which can be attributed to modification of the (L178-R219) peptide fragment by 2a (232 
Da).  Adapted from (Dutta et al. 2010). 
4500 Da 
4268 Da 
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3.3  Inhibition studies of human AChE in presence of laboratory synthesized 
natural product cyclophostin: 
3.3.1  Test of IC50s of the natural and unnatural product of cyclophostin: 
Like the phosphonate analog of cyclophostin, our collaborator supplied us with 
two diastereoisomeric forms of the natural product.  This was because the phosphate 
starting material is achiral and can only yield two of the four isomers.  In the structure of 
natural product cyclophostin, the methoxy group and the ring junction hydrogen are on 
the same side of the molecule.  Our collaborator synthesized two isomers of 
cyclophostin, a) natural isomer of cyclophostin, having methoxy group and the ring 
junction hydrogen that are on the same side of the molecule, and b) unnatural product of 
cyclophostin, having the methoxy group and the ring junction hydrogen on opposite sides 
of the molecule (Table 3.3). 
Like the cyclophosphonate analogs of cyclophostin, the IC50s of both of the 
isomers were determined using Ellman‟s assay (Ellman et al. 1961).  The IC50 obtained 
for both of the isomers were around 40 nM (Table 3.3).  Improved potency of the natural 
product compared to cyclophosphonate analog of cyclophostin was expected but not to 
the extent it actually exhibited (almost 1000 times more).  Surprisingly, unlike 2a and 2b, 
the natural and unnatural product showed no diastereospecificity.  It is possible that the 
presence of oxygen at the position 5 of the natural product makes the P-centre highly 
electrophilic, which minimizes the diastereospecificity towards the AChE active site.  
Synthesis and activity tests of the other two isomers of the natural product may 
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Table 3.3:  Potency of natural and unnatural isomer of cyclophostin against human 
AChE. 
Compound 
 
 IC50 (nM) 
 
26 
 
Natural 
Product 
 
 40 
27 Unnatural 
Product 
 
 35 
 
Natural product isomer of cyclophostin:  The junction H-atom and the OMe group 
attached to the P-centre are on the same side of the molecule. 
Unnatural product isomer of cyclophostin:  The junction H-atom and the OMe group 
attached to the P-centre are on the opposite side of the molecule. 
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bring some light to this issue.   
3.3.2  Mechanism of inhibition of human AChE by natural (compound 26) and 
unnatural cyclophostin (compound 27):   
Since there is not much difference between the structure of the cyclic 
phosphonate analog of cyclophostin and the natural product, the test of irreversibility of 
the reaction of natural product and human AChE was performed.  Both natural and 
unnatural isomers (100 nM) were incubated with human AChE and subjected to P6DG 
desalting column purification as discussed above.  The eluted fractions of enzyme at the 
void volume for both isomers were re-quantitated and assayed.  Fig. 3.9 shows that for 
both isomers, the enzyme obtained after elution was inactive, again indicating the 
irreversible type of inactivation of this class of compound.   
To determine the exact mechanism of inhibition, % residual activity of enzyme 
was recorded as a function of inhibitor concentration and incubation time for both the 
isomers against human AChE (Fig. 3.10).  To obtain the equilibrium inhibition constant 
(KI), forward rate constants for inactivation (k2), and reverse rate constants for 
inactivation (k-2), Model 1 was utilized and the data were analyzed the same way 
described above for compound 2a inhibition of AChE.  The natural product and the 
unnatural product isomer showed similar equilibrium inhibition constant (KI) which is 
consistent of their corresponding IC50s (Fig. 3.10 and Table 3.4).  Surprisingly, the 
forward rate constants for inactivation (k2) for both isomers were only 2-3 times higher  
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Fig. 3.9:  Test of irreversibility of natural/unnatural (26/27) isomer-human AChE 
reaction. 
A:  10 nM human AChE was incubated with 150 nM of natural isomer 26 for 30 mins at 
25C in 20 mM Tris-Cl, pH-7.5 and passed through P6DG desalting column.  The 
enzyme was collected at the void volume, re-quantitated and assayed for activity.  E 
represents the activity of the enzyme incubated in buffer for 30 min and subjected to 
desalting.  E + I represents the % residual activity of enzyme treated with inhibitor for 30 
min but not desalted.  The average activity for three trials was 2.0 % of initial activity.  E 
+ I + P6DG represents the activity of enzyme incubated with inhibitor for 30 min and 
purified by desalting gel.  B:  The same analysis performed with 10 nM human AChE in 
presence of 150 nM of unnatural isomer 27.  Error bars were generated from three 
independent experiments. 
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Fig. 3.10:  Kinetics of inhibition of human AChE in presence of natural and 
unnatural isomer (26 and 27).  The left column shows % residual activity as a function 
of pre-incubation time.  Right column shows the kobs (min
-1) as of function of inhibitor 
(nM).  The kobss in right column were obtained from the % residual activity vs pre-
incubation time plot at the left column using Model 1.  The data in kobs (min
-1) vs 
inhibitor (nM) plot at the right column were fit with Eqn 2 (see Chapter II) to obtain KI, 
k2, and k-2.  Upper panel shows the kinetic study of natural product 26 against human 
AChE; natural product = 10 (black circle), 20 (blue squares), 40 (pink diamonds), 80 
(green triangles), and 160 nM (grey inverted triangle).  The lower panel shows the kinetic 
study of unnatural product 27 against human AChE; unnatural product = 10, 20, 40, 80, 
and 160 nM (symbols as above).  Human AChE = 10 nM. 
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Table 3.4:  Kinetic parameters of inhibition of human AChE by natural (26) and 
unnatural isomer (27). 
Compound 
Kinetic Parameters 
KI 
(nM) 
k2 (min
-1
) k-2 (min
-1
) 
26 
 
115±60 0.7±0.1 0 
27 
 
224±95 0.9±0.2 0 
95 
 
than that of the most potent µM range cyclophosphonate analogs of cyclophostin.  It was 
bit surprising that the natural product having highly electrophilic phosphate P-centre did 
not show much difference in forward rate constants for inactivation (k2) compared to 
phosphonate analog.  The low values of reverse rate constants for inactivation (k-2) for 
both the isomers explain a little bit of the above stated paradox.  It is possible that 
insignificantly low values of reverse rate constants for inactivation (k-2) contributed more 
towards the high potency of the natural product rather than the forward rate constants for 
inactivation (k2) values.   
3.3.3  Oxime reactivation of natural/unnatural product (26/27)-AChE complex: 
Like cyclic phosphonate analogs, the natural and unnatural product isomers of 
cyclophostin exhibit a similar mechanism of inhibition against AChE, but with higher 
potential.  Assuming that the isomers also covalently modify the active site serine, oxime 
reactivation experiments were conducted.  Human AChE was incubated with 
natural/unnatural isomers of cyclophostin and subsequently reacted with pralidoxime and 
assayed for the activity.  Like cyclicphosphonate case, both the isomers showed only 
residual reactivation (Fig. 3.11).  The best way to address this issue is to get high 
resolution mass spectroscopy data of the trypsinized natural/unnatural isomer-AChE 
complex and look for probable peaks generated due to the mechanism route shown in 
Fig. 3.6 or other mechanisms.  It would also be instructive to perform reactivation kinetic 
studies of the complex using different oximes, to check for oxime specificity of the 
reaction.   
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Fig. 3.11:  Pralidoxime reactivation of human AChE-natural/unnatural isomer 
complex.  A:  10 nM human AChE was incubated with 100 nM of natural isomer 26 for 
30 mins at 25°C in 20 mM Tris-Cl, pH-7.5.  35 mM pralidoxime was introduced and % 
residual activity of enzyme was checked.  E + P, enzyme and pralidoxime control. E + I, 
enzyme and inhibitor control.  E + I + P, enzyme and inhibitor and pralidoxime (see 
Chapter II).  All rates are expressed relative to the enzyme control at the same time 
point in the experiment.  B:  Same analysis was done with 10 nM human AChE in 
presence of 100 nM of unnatural isomer 27 and 35 mM pralidoxime. 
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CHAPTER IV 
INHIBITION STUDIES OF RAT HORMONE-SENSITIVE LIPASE 
AND ITS PHOSPHORYLATION-INDUCED TRANSLOCATION IN 
3T3-L1 CELLS 
4.1  Structure-activity relationship of laboratory synthesized inhibitors of hormone-
sensitive lipase HSL: 
As discussed in Chapter I, hormone-sensitive lipase (HSL) is another SH family 
member like AChE.  The active site of HSL contains a conserved serine residue, which 
acts as the nucleophile to attack the substrate‟s electrophilic centre (carbonyl C-atom).  
Though the exact geometry and structure of HSL‟s active site is still not known, it is 
shown from the mutational and modeling studies that unlike other esterases, the active 
site is hydrophobic and its activity largely dependent on hormone induction (Fredrikson 
et al. 1981; Osterlund et al. 1996; Anthonsen et al. 1998).  It is proposed that hormone 
induction triggers structural changes in both regulatory and N-terminal domain, which in 
turn affects the activity of the enzyme. 
HSL hydrolyzes lipids in the form of mono-, di-, and tri-acyl glycerols (MAG, 
DAG, and TAG) in vitro and in vivo (Fredrikson et al. 1981; Vossler et al. 1997; Shen et 
al. 1998).  It has been reported that HSL can also hydrolyze organic esters like p-nitro 
phenyl butyrate (p-NPB) in vitro (Smith et al. 1996).  It has been shown in the literature 
that limited proteolysis of HSL can destroy the lipase activity (TAG hydrolysis) but not 
the esterase activity (Smith et al. 1996). 
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Due to the HSL‟s direct role in lipid homeostasis, it is often associated with 
diabetes type-II, obesity and atherosclerosis disease conditions (Ylitalo et al. 2000; 
Hoffstedt et al. 2001; Teruel et al. 2005; Palou et al. 2009; Ishihara et al. 2010).  
Researchers have proposed that one of the ways to control abnormal lipid homeostasis in 
the insulin resistance state is to minimize the hydrolysis of TAG.  One of the best ways 
to hinder the TAG hydrolysis is to inhibit the normal activity of HSL.  Though according 
to some researchers tri-acyl glycerol lipase (ATGL) can also be targeted for the above 
purpose, HSL is still a best candidate due to its involvement in hormone regulated 
reaction cascade in adipose tissue (Kim et al. 2006; Schoenborn et al. 2006; Jocken et al. 
2008). 
4.1.1  Test of IC50s for laboratory synthesized organophosphates (OP) against rat 
hormone-sensitive lipase (HSL): 
Several potent HSL inhibitors have been reported in the literature (Table 1.3 in 
Chapter I).  All of the inhibitors are shown in Table 1.3 are laboratory synthesized 
(Claus et al. 2005; Ben Ali et al. 2006).  Mostly these inhibitors contain ester groups or 
lactone rings.  However, almost all of the inhibitors reported to inhibit the lipase activity 
of the enzyme as well (Slee et al. 2003; de Jong et al. 2004; Ben Ali et al. 2006).  Though 
it is well established from mass spectrometric data that these above compounds 
covalently modify the HSL active site, there is not much information available regarding 
the initial binding or secondary interactions of aromatic substituent of the inhibitors with 
active site residues of the enzyme.   
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Vertesy et. al. has reported the isolation and potency of cyclipostin, a natural 
product HSL inhibitor (Table 1.4 in Chapter I).  Cyclipostin is the first natural product 
inhibitor ever reported for HSL.  The IC50 of cyclipostin against HSL is in the low nM 
range.  The core structure of the compound is composed of a seven-membered phosphate 
ring fused with a five-membered lactone ring.  The central P-atom has O-alkyl 
substitutions of variable C-chain length.  Based on the data presented in Chapter III, it 
can be extrapolated that cyclipostin modifies the in HSL active site.  In addition, the 
presence of the long C-chain substitution may facilitate the initial binding of the 
compound with hydrophobic residues in HSL active site. 
Table 4.1 shows the list of compounds that we have tested to date against rat 
HSL.  Except DIFP and compound 6 all other compounds have same core structure 
featuring a monocyclic seven-membered phosphonate ring and a C-chain at the 5 
position.  Compound 22a and b, 23a and b, and 24a and b have six, ten and twelve C-
chain moieties at their 5 positions, respectively.  To evaluate the compounds‟ potency, 
the activity of rat HSL in presence of the inhibitors was tested using both esterase and 
lipase assays (experimental procedure in Chapter II).  For esterase and lipase assays, p-
NPB and 9, 10-H3-labelled triolein have been used as substrates, respectively.  To test the 
validity of the HSL assay, the IC50 of DIFP has been tested using both esterase and lipase 
assays.  The IC50s of DIFP obtained for both esterase and lipase assays closely 
corroborated with the literature data of 50 µM (Holm et al. 1989; Holm et al. 1991) and 
validated the assay procedure. 
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Table 4.1:  IC50s of laboratory synthesized HSL inhibitors. 
 
N.A – Not Applicable. 
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Compound 6 showed almost 18 and 36 fold less reactivity towards HSL in terms 
of esterase and lipase activity compared to AChE.  This indicates that compound 6 is 
more specific for AChE active site and behaves more like the conventional AChE 
inhibitor DIFP.  Compound 22a, 23a, and 24a have same diastereomeric structure having 
the methoxy group and the H5 on opposite sides of the ring, whereas 22b, 23b, and 24b 
have methoxy and H5 on the same side of the ring.  Rat HSL showed diastereo specificity 
towards 22a and 23a over 22b and 23b in terms of esterase activity.  The compounds did 
not show the same trend in terms of lipase activity.  Surprisingly, both 24a and 24b 
showed no potency against rat HSL when esterase activity was tested.  The improved 
potency was noticed in lipase activity when the C-chain length was increased to C12 in 
24b.  Both 24a and b did not show any activity in HSL esterase assay.  Finally, it is 
revealed from the result in Table 4.1 that compounds 22 to 24 do not show a real trend in 
terms of structure-activity relationship (SAR).  The compounds 22 to 24 have the same 
core structure like compound 9 in Table 3.1; 9 being an efficient cholinesterase inhibitor, 
it was expected that the compounds in Table 4.1 would at least exhibit some activity in 
HSL esterase assay. 
4.1.2  Effect of liposome composition on inhibitor activity: 
It is well established in the literature that the ratio of liposome constituting 
materials phophatidylcholine (PC) and phosphatidylinositol (PI) has a considerable effect 
on the activity of lipase enzymes (Ali et al. 2005; Petry et al. 2005).  As mentioned in 
Chapter II, the inhibitors containing long chain C-chain were introduced to the rat HSL 
in liposome forms.  Generally, the ratio of PC/PI was kept 1:3 to form the liposome.  It is 
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not desirable to form large and multi-lamellar liposome entities containing the payload 
materials due to the limited accessibility of the enzyme.  Considering this fact, the 
liposome composition ratio was changed to 1:2 (PC/PI) and the IC50s of the compounds 
re-determined.  Table 4.1 shows the IC50s of the compounds embedded in liposome 
containing PC/PI 1:2.  It is revealed from the result that the change in the PC/PI ratio did 
not improve the potencies of the compounds. 
4.2  In vitro fluorescence studies of rat HSL’s hydrophobic surface exposure upon 
phosphorylation:   
As discussed in Chapter I, HSL translocates from the cytoplasm to the lipid 
droplet upon hormone induced phosphorylation (Fig. 1.15).  Krintel et al. (2009), has 
proven in vitro that upon PKA induced phosphorylation, the total hydrophobic surface 
area of HSL increases.  This hydrophobic surface area enhancement may play a vital role 
in HSL‟s translocation from cytoplasm to lipid droplets in vivo.  Krintel et al. (2009), has 
shown that phosphorylation leads to hydrophobic surface exposure but has not dissected 
the role of different phosphorylation sites in their work.  It is possible that the surface 
exposure is an accumulative result of phosphorylation of all PKA- phosphorylation sites 
or it is just a single site phenomenon.  This dissertation deals with this question by 
mutating the phosphorylation sites of rat HSL and testing the surface exposure 
phenomena. 
The phenomena of hydrophobic surface exposure has been tested by exposing the protein 
to 1-anilinonaphthalene 8-sulfonate (ANS), an organic compound that binds with the 
hydrophobic surface of the protein and exhibits dramatic emission enhancement at 470 
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nm (detail in Chapter II).  Fig. 4.1A shows that HSL dephosphorylated using protein 
phosphatases-2A (PP2ase) results in a decrease in the emission of ANS relative to 
partially phosphorylated HSL as purified from Sf9 cells.  This result is consistent with 
Krintel et al.  The same experiment has been done with rat HSL mutated to alanine at 
both the basal phosphorylation site S565 and regulatory phosphorylation site S563.  Fig. 
4.1B reveals that the partially phosphorylated and completely phosphorylated 
S563A/S565A double mutant behave similarly.  It seems that either both basal and 
regulatory phosphorylation sites do not have considerable control on the exposure 
phenomena or it is a cumulative effect that involves the phosphorylation of all four PKA-
dependent phosphorylation sites including S659 and S660.  It is possible that the basal 
site S565 may not have any direct influence on the phosphorylation but as it influences 
the phosphorylation at S563, the indirect contribution of this site towards the exposure 
phenomena cannot be ruled out. 
4.3  In vivo studies of rat HSL translocation from cytoplasm to lipid droplets in 3T3-
L1 cells: 
Though translocation of HSL to the lipid droplets does not always lead to the successful 
hydrolysis of lipids, the translocation process is one of the most vital steps in the reaction 
cascade of lipid homeostasis.  As discussed in Chapter I, an eight amino acid 
hydrophobic patch (F734LSLAALC741) at the C-terminal domain of the rat HSL may 
contribute to the translocation process (Holm et al. 1988).  The role of the hydrophobic 
patch in lipid binding has not yet been demonstrated experimentally and the speculated 
role of its contribution in HSL‟s translocation process needs to be tested.  In this part of 
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Fig. 4.1:  ANS binding to rat HSL to probe the hydrophobic surface exposure.   
A:  ANS binding has been done with wild type rat HSL at two different conditions; 
ANS-wild type HSL (red curve) and ANS-PP2ase treated wild type HSL (blue curve) in 
50 mM Tris, pH 7.5 at 25ºC (see Chapter II).  ANS has been excited at 380 nm and the 
emission has been recorded from 450 to 650 nm.  The green curve represents the ANS-
PP2ase emission.  B:  Same experiment has been done with double mutant HSL 
(S563A/S565A).  Red, green, and blue curves represent the ANS binding with mutant 
HSL, PP2ase treated mutant HSL, and PP2ase and okadaic acid treated mutant HSL, 
respectively. 
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dissertation, the above hypothesis is examined in 3T3-L1 pre-adipocyte cells. 
Researchers have long been using the 3T3-L1 pre-adipocyte cell system to study 
the different aspects of lipid metabolism (Wolins et al. 2005; Wolins et al. 2006; 
Granneman et al. 2007).  Generally, the pre-adipocyte cells are differentiated to mature 
adipocytes so that the cells can store the lipid as lipid droplets (experimental detail in 
Chapter II).  It has been established that 3T3-L1 pre-adipocytes can easily be transiently 
transfected to introduce genetic material in the cell for protein expression purposes 
(detail in Chapter II) (Granneman et al. 2007).  To follow the translocation process of 
HSL upon phosphorylation, the protein has been tagged with yellow fluorescent protein 
(YFP) and the expression has been observed using confocal microscope (Fig. 2.4). 
As HSL translocates from the cytoplasm to lipid droplets, it is important that the 
cells mature and form lipid droplets.  To pursue the process, after transfection the cells 
have been chemically differentiated and the lipid droplets are chemically tagged with 
BODIPY-C12 (detail in Chapter II).  Fig. 4.2 shows the co-localization of YFP-HSL and 
BODIPY-C12 labeled lipid droplets in fully differentiated 3T3-L1 cells. 
Using YFP as the potential donor and BODIPY as the acceptor fluorophore; the 
proximity of the HSL and lipid droplet has been tested by using Forster Resonance 
Energy Transfer (FRET).  As shown in Fig. 4.2, FRET has been performed by exciting 
the donor fluorophore at 488 nm and monitoring the increase in acceptor emission at 510 
nm.  FRET has also been attempted using the „acceptor photo-bleaching‟ method, where 
the acceptor has been photo-bleached at 504 nm and the increase in the donor emission is 
monitored (Fig. 4.3).  Unfortunately, not even 5% increase of donor emission has been  
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Fig. 4.2:  BODIPY-C12 stained differentiated YFP-HSL transfected 3T3-L1 cells.  
The YFP-HSL transfected 3T3-L1 cells were differentiated (protocol mentioned in the 
text) and then the cells were stained with BODIPY-C12 (20 µg/ml) for 1 hr at 37ºC 
(protocol in the above text).  The cells were washed with PBS three times and confocal 
image was taken.  The picture was taken using Zeiss confocal imaging microscope (CNS, 
UMSL) with the following parameter set:  Track 1 for BODIPY:  lens: 63X, laser power 
master gain = 235, pin hole = 1AU, excitation at 488 nm and emission at 510 nm in 
Smart setup; track 2 YFP:  lens: 63X, laser power master gain = 350, pin hole = 1AU, 
excitation at 488 nm and emission at 504 nm in Smart setup; track 3:  lens: 63X, laser 
power master gain = 304, pin hole = 1AU, transmitted light (T-PMT) in Smart setup.   
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Fig. 4.3:  FRET experiment to access HSL translocation to lipid droplet.  
Transfection and the lipid staining have been done the same as described in Fig. 4.2.  The 
confocal microscope has been set up same as Fig. 4.2, except for the FRET experiment, 
where the three channel mode has been activated.  FRET has been performed using the 
acceptor photo bleaching method, where the donor has been excited at 488 nm and the 
acceptor has been photo-bleached at 504 nm.  The donor emission enhancement was 
monitored every 10 msec for 100 msec.  In the series mode, the stop option was kept „on‟ 
when the intensity increase goes up to 10 %. 
10 msec 20 msec 30 msec 40 msec 
50 msec 60 msec 70 msec 80 msec 
90 msec 100 msec 
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noticed in this process, which indicates that for some technical reason FRET has not been 
successful.   
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CHAPTER V 
DISCUSSION 
5.1  Comparison of potency of laboratory synthesized OPs with the commercially 
available OPs against human AChE: 
The kinetic studies of AChE in presence of different analogs of cyclophostin 
reveal that both mono- and bi-cyclic compounds are low µM inhibitors and generally 
exhibit µM inhibition equilibrium constant.  Moreover, these classes of compounds 
behave very similarly to DIFP, a commonly used organophosphate inhibitor for AChE.  
It is also revealed from Table 3.2 that they are less potent than DIFP in terms of IC50s, 
KI, k2, and k-2.  Apart from compound 2a‟s species-specific activity that identified the 
compound as a potential insecticide candidate, it was necessary to compare 2a and other 
compounds of its class to the other literature reported OPs.   
For the above purpose, the potency of 2a, 2b, and 9 were compared with other 
OPs in terms of  the KI and kinact parameters obtained using Model 2 (simplified version 
of Model 1 explained in Chapter II) (Walker et al. 2001).  From KI and kinact, the ki, a 
first order rate of inactivation, was calculated and compared with the literature values of 
kis of other OPs.  The reproducibility of experimental and literature value of ki of DIFP 
(experimental value 1.4 e5 M-1 min-1 and literature value 1.3 e5 M-1 min-1) authenticated 
our method (Table 5.1).  Table 5.1 shows that 2a, 2b and 9 have two orders of 
magnitude smaller ki than that of the DIFP and three to five orders of magnitude smaller  
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Table 5.1:  Comparison of first order rate of inactivation (ki) of OPs against human 
AChE. 
Compound         Structure Kinetic parameters 
ki (M
-1 min-1) 
 
2aa 
 
 
  
9 x 103 
 
 
2.5 x 103 
 
 
2.7 x 103 
 
 
1.4 x 104 
 
 
1.4 x 105/1.3 x 105 
 
 
 
4.0 x 105 
 
 
 
9.5 x 105 
 
 
 
7.4 x 106 
 
 
9.2 x 107 
 
 
 
1.2 x 108 
 
2ba  
9a  
 
15a 
 
 
DIFPa, b 
 
 
DEFPa, c 
 
Paraoxona, c  
 
 
Tabuna, b 
 
 
Somana, b 
 
 
VXa, b 
 
 
ki was calculated from kinact/KI for each compound using Model 2 (Chapter II). 
a(Dutta et al. 2010); b(Worek et al. 2004); c(Ordentlich et al. 1993). 
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than those of tabun, soman, and VX (Worek et al. 2004; Dutta et al. 2010).  This result 
indicates that the 2a and 9 are much milder and less toxic than the other laboratory 
synthesized OPs, and can be potential Alzheimer‟s disease drug candidates.  
On the other hand, the low nM potency of the natural and unnatural product of 
cyclophostin (compound 26 and 27 respectively) (Table 3.4) indicated that cyclic 
phosphate ring system has a unique ability to bind the AChE active site.  This opened a 
new avenue to design potent inhibitors having similar cyclicphosphate-lactone bicyclic 
entity which was unknown before the analysis done in this dissertation.   
5.2  Probable reasons for less potency of compound 22 to 24 against rat HSL: 
One of the possible reasons of poor potency of these series of compounds may lie 
in their structures.  The structures of compound 22 to 24 differ far from the naturally 
occurring potent cyclipostin inhibitors (Fig. 5.1).  As is obvious from Fig. 5.1, the C-
chain moiety is attached to the P-center as an alkoxy substituent in cyclipostin, whereas 
in compounds 22 to 24 the C-chain is attached to the C5 ring carbon.  It is possible that 
for successful binding as well as covalent modification of the HSL active site, it is 
essential to have the C-chain at the P-center.  To put more light onto this matter, the C-
terminal domain of HSL was modeled (Fig. 5.2) using the method called secondary 
structure aided multiple sequence alignment (SSAMSA) using SwissPDB Viewer tool 
(Guex and Peitsch 1997) (see Chapter II for details).   Both 24 and cyclipostin were 
manually docked at the active site.  Fig. 5.3A and B shows the docking results that 
indicate that if the C-chain is attached at the C5 position, there will be less probability 
that 24 will orient in a way that successfully leads to the binding  
112 
 
 
 
 
 
 
 
Compound 25 
Fig. 5.1:  Structural difference of cyclipostin and compound 22-25.  Cyclipostin 
contains the O-alkoxy group having the long C-chain (red square) that is attached to the 
P-center, whereas the C-chain is attached at the C5 in 22-24.  Moreover, cyclipostin has a 
five-membered lactone ring that is absent in 22-24.  Compound 25 is also shown in this 
figure where there is a C16 C-chain is attached directly to the seven membered ring P-
atom (green box).  The structure is very similar to the natural product cyclipostin except 
its monocyclic entity. 
Cyclipostin Compound 22-24 
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Fig. 5.2:  Backbone structure of C-terminal domain of rat HSL.  The C-terminal 
domain sequence (residues 300 to 767) of rat HSL has been fed to the SwissPDB viewer 
tool and the model has been obtained by using the Candida rugosa lipase (CRL) as 
template.  The active site catalytic triad residues are shown in red.  The discontinuity at 
the structure is due to the non-homologous sequence in rat HSL compared to CRL.  The 
analysis is based on structure aided multiple sequence alignment (SSAMSA) which is 
termed as „magic fit‟ in Swiss PDB viewer (Guex and Peitsch 1997) (more detail in 
Chapter II).   
Ser423 
His733 
Asp703 
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Fig. 5.3:  Simplified docking model of cyclipostin and 24 in HSL active site.  A:  
Cyclipostin has been manually docked in the rat HSL C-terminal domain that has been 
modeled (Fig. 5.2) using Candida rugosa lipase as a template.  The P-center of 
cyclipostin is within a covalent bond distance of the O-atom of serine (~1.65 Å) and the 
long C-chain directs towards the acyl-binding site (ABS; pink cylinder) (residue 442-
453).  B:  24 has been docked in rat HSL C-terminal domain.  Keeping the serine O-atom 
P-center distance constant as 1.6 Å, the long C-chain directs opposite to the ABS.   
 
B 
ABS 
ABS 
A 
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of C-chain to the acyl-binding site (ABS) and as well as the covalent modification at the 
active site serine.  Improved potency of compound 25 (Fig. 5.1; Table 4.1) supports this 
above hypothesis.   
The improved potency of monocyclic compound 25 (IC50: lipase activity-30 µM) 
(Table 4.1 and Fig. 5.1) having C16 C-chain attached with O-atom of P-O functionality 
somehow corroborates with the above hypothesis but the potency still could not reach the 
nM range against rat HSL.  Moreover, the compound did not show any esterase related 
activity.   
Another possible reason for better potency of cyclipostin is that the O-atom (as H-
bond acceptor) at the carbonyl function of the lactone ring at the bicyclic entity of the 
cyclipostin may involve in some secondary interactions with H-bond donor residues at 
the active site that are absent in 24.   
5.2.1  Compound 24 aggregation in aqueous solution and Dynamic light scattering 
(DLS) experiment: 
It is a well known fact that molecules with long C-chains often aggregate in 
aqueous solution.  If compound 22 to 24 aggregate in the buffer solution used, then it is 
possible that the aggregated form of the molecules will not be accessible to the enzyme.  
Compound 22-24 does not carry any charge in their structure which is very similar to 
triolein, the natural substrate of HSL.  In general, the triolein are introduced to the 
enzyme in the form of liposome, a well-defined aggregated form, otherwise it might 
aggregate randomly in aqueous solution and could be inaccessible to the enzyme.   
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Fig. 5.4:  Dynamic Light Scattering (DLS) experiment of 24.  In all of the above three 
figures, the following experimental conditions are constant: temperature = 25°C, dust cut 
off = 40.00, run = 4, angle = 90º, assumption of shape = shell, time = 3 mins.  A:  24 = 2 
µM, average count rate (ACR) = 154.4 cps, polydispersity = 0.217, effective diameter = 
311.0 nm and baseline index = 9.3/100%; B:  24 = 125 µM, average count rate (ACR) = 
380.4 cps, polydispersity = 0.208, effective diameter = 320.0 nm and baseline index = 
9.3/74.4%; C:  24 = 125 µM in liposome having PC/PI=1/3, average count rate (ACR) = 
439.5 cps, polydispersity = 0.209, effective diameter = 386.8 nm and baseline index = 
6.4/30.19%.  The additional peak that is observed at the lower diameter region in all 
cases is likely a contamination.  High contamination observed in C was due to the low 
dust cut-off selected for the experiment. 
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Similarly, for compound 22-24 it is possible that due to their aggregation nature the 
potency of the compounds are underestimated.  To determine if aggregation is one of the 
reasons for reduced potency of these classes of compounds, Dynamic Light Scattering 
(DLS) experiments (experimental detail in Chapter II) was performed on 24b both in 
normal and liposome embedded forms.  Fig. 5.4A, B, and C shows the DLS data of 24 
where it is evident that even at 2 µM concentration, 24 has formed some sort of 
aggregated entity whose average diameter is ~450 nm (Fig. 5.4A).  At 125 µM, the 
aggregated particle is larger (~600 nm) (Fig. 5.4B).  Surprisingly, liposome-embedded 
24 formed smaller particles (~250 nm) than the normal one at 125 µM (Fig. 5.4B and C).  
It is evident from the above data that laboratory synthesized analogs of cyclipostin 
aggregates in the aqueous solution.  It is possible that HSL does not have access towards 
the business end of the molecule due to aggregation that leads to impaired inhibition in 
presence of this class of inhibitors. 
To test the above hypotheses, the synthesis of cyclipostin is necessary.  Kinetic, 
crystallographic and modeling studies of HSL in presence of cyclipostin may bring more 
light to this issue.  This dissertation has contributed towards the initiation of the kinetic 
studies of analogs of cyclipostin against rat HSL that may help in the search for potential 
drugs against obesity and diabetes type II. 
5.3  Phosphorylation induced translocation of rat HSL: 
The biophysical characterization of the conformational change of rat HSL upon 
hormone-induced phosphorylation may ultimately contribute to the development of 
potent inhibitor against HSL.  Chapter III has provided evidence that the 
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conformational change of HSL during the translocation towards lipid droplets is actually 
a hydrophobic surface exposure.  In vivo experiments have been initiated to complement 
the above observation and multiple mutations have been constructed to identify the 
region of exposure.  Moreover, preliminary data of the effect of phosphorylation on HSL 
is also provided.  It is established that S563 and S565 have very little or no effect on the 
hydrophobic surface exposure of HSL upon phosphorylation.  These results have opened 
multiple scopes to study the most interesting characteristics of HSL both in vitro and in 
vivo.   
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